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Abstract 
    The KRAS mRNA is one of few oncogenic mRNAs that can be recognized and 
bound by the RNA-binding protein called Coding Region Determinant-Binding Protein 
(CRD-BP). Binding of CRD-BP to oncogenic mRNAs can ultimately increase the 
possibility of tumor occurrence. Given that CRD-BP is only expressed in adult cancers 
but not in normal tissues, targeting the CRD-BP-mRNA interaction is a good anti-cancer 
strategy. To study CRD-BP-KRAS mRNA interaction and to search for inhibitors of such 
interaction, a safe, sensitive and high throughput-based fluorescence polarization (FP) 
method was developed. By using a 44 nts fluorescein-labeled KRAS RNA, a library of 
217 small molecules was screened for their ability to inhibit CRD-BP-KRAS RNA 
interaction. Finally, candidate small molecule inhibitors as well as effective antisense 
oligonucleotides (AONs) against KRAS RNA were assessed for their ability to suppress 
KRAS gene expression in cancer cells. 
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CHAPTER 1 Introduction 
1.1 Gene expression and its relationship with diseases 
In cells, genetic information is first passed from genomic DNA to RNA via 
transcription, and proteins are then generated through translation, as is described in the 
Central Dogma (Crick, 1970). Although the basic principle looks simple, gene expression 
is actually a very complex and delicate process. Before the genetic code within DNA is 
successfully expressed to functional molecules in cells, many steps including RNA 
editing, RNA and protein modification, RNA and protein transportation are required. 
However, it is difficult to ensure everything goes exactly as biologically planned in such a 
complex expression system. Even a slight error in any step of the gene expression process 
can potentially lead to disease occurrence.  
It is now known that there is a close relationship between the regulation of gene 
expression and human diseases. Nucleotide replacement in an mRNA coding region may 
lead to an unpredictable change in protein sequence or structure. For instance, C to U 
editing in mRNA of apolipoprotein B (Apo B) induces a stop codon and changes the 
length of Apo B, which leads to atherosclerosis (Maas and Rich, 2000). Another example 
is retinitis pigmentosa, a genetic disease caused by a change in alternative splicing (Tazi 
et. al., 2009). Non-coding RNAs (ncRNAs), such as miRNA, are also important gene 
regulators, as they can trigger gene silencing in RNA transcriptional, post-transcriptional 
regulation and chromatin modification (Taft et. al., 2010). Variants in ncRNAs may also 
cause cancers (Hu et. al., 2008; Shen et. al., 2009; Calin et. al., 2005) and hearing loss 
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(Lewis et. al., 2009). 
1.2 mRNA Stability and mRNA Degradation Pathways 
1.2.1 mRNA decay pathways 
mRNA is transcribed from genomic DNA and then used as a template in translation. 
When its mission is completed, mRNA is subjected to degradation. To remain stable 
during transcription and translation, mRNA is protected by a methylguanylate cap at its 5’ 
end and a poly A tail at its 3’ end. Eukaryotic initiation factor (eIF4E) and 
poly(A)-binding protein (PABP) also bind to the 5’ and 3’ ends respectively to help 
stabilize mRNA and initiate translation (Kahvejian et. al., 2005, Jones et. al., 1997). If 
mRNA is decapped, deadenylated or cleaved endonucleolytically, the body of mRNA is 
subjected to degradation. The mRNA decay mechanisms are critical in controlling gene 
expression, antiviral defenses and degrading aberrant mRNAs (Parker and Song, 2004). 
There are three general mRNA decay pathways in eukaryotes, which include the 
deadenylation-dependent mRNA decay, the deadenylation-independent mRNA decay, and 
the endonuclease-mediated mRNA decay (Garneau et. al., 2007). Therein, poly-A tail of 
mRNA would be shortened when mRNA is reused during translation procedure. Through 
the deadenylation-dependent mRNA decay, which is believed to be the predominant 
decay pathway, mRNAs are saved to some extent. 
When RNA decays from 5’→3’ direction in deadenylation-dependent pathway, 
Lsm1-7 protein complex binds to the 3’end of mRNA, which is deadenylated by CCR4 
NOT complex or PARN trimer. After that, Dcp1/Dcp2 decapping protein complex decaps 
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the 5’ end of mRNA, resulting in a 5’→3’ decay by exoribonucleases XRN1. In 3’→5’ 
decay pathway, the exposed 3’end of mRNA is degraded by exosome complex. Upon 
decay to short oligonucleotides, mRNA is decapped by scavenger decapping protein 
(Garneau et. al., 2007). 
In deadenylatoin-independent mRNA decay, protein subunits Edc3 and Rps28B bind 
close to the poly A tail of mRNA, followed by recruitment of Dcp1/Dcp2 complex to 
decap the 5’ end (Garneau et. al., 2007). Lastly, mRNA decays from the 5’ to 3’ direction 
by XRN1. Similar to deadenylation-dependent decay, mRNAs can be degraded from both 
sides in endonuclease-mediated mRNA decay pathway. But this mechanism first requires 
endonuclease (such as RNase MRP) to cleave within the body of mRNAs, after which 
mRNAs decay from both sides by the exosome complex (5’ cleaved product, 3’→5’) and 
ERN1 (3’ cleaved product, 5’→3’). 
In addition to the general decay pathways, there are three other surveillance mRNA 
decay pathways that degrade aberrant mRNAs. These pathways largely help to maintain 
gene fidelity during translation, which further underscores the critical role of mRNA 
turnover in gene expression.  
In the non-sense mediated decay (NMD), the exon junction complex (EJC) and the 
premature termination codon (PTC) are detected and trigger mRNA decay. UPF2 first 
binds to the EJC in the cytoplasm. When a ribosome meets PTC, it stops translation and 
then is bound by the SURF protein complex. UPF2 associates with SURF complex, 
through which EJC and PTC are joined together. Finally, SMG1 kinase phosphorylate 
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UPF1 located in SURF, releasing eRF1 and eRF3 and recruiting SMG7 adaptor protein, 
leading to mRNA decay (Garneau et. al., 2007). 
In the non-stop decay (NSD), when there is no stop codon and the ribosome runs 
through the whole mRNA until it reaches the 3’ termini poly A tail. Ribosome replaces 
PABP, and RNA is then degraded by one of two different mechanisms according to the 
presence of Ski7 tRNA mimic protein. If Ski7 binds to ribosome, mRNA is released to be 
decayed by exosome complex from the 3’ to 5’ direction. If there is no Ski7, mRNA is 
easily decapped for the PABP absence, which results in 5’-3’ decay by Xrn1 (Garneau et. 
al., 2007).  
The last surveillance pathway is no-go decay (NGD), in which Dom34-Hbs1 
complex simulates endonucleolytic cleavage near the ribosome that stalled due to a strong 
mRNA secondary structure. The two cleaved mRNA decay products are then degraded by 
exosome and Xrn1 from both sides of mRNA (Garneau et. al., 2007). 
1.2.2 Regulators of mRNA stability: cis- elements and trans-acting factors 
mRNA stability is largely controlled by two major components, the mRNA sequence 
itself known as cis-elements (such as iron response element, AU-rich element and 
sequences in the coding region) and trans-acting factors (such as ribonucleases, 
non-coding RNAs and RNA-binding proteins). RNA-binding proteins will be discussed 
in detail in section 1.3. 
For example, interaction between an iron response element (IRE) and an iron 
regulatory protein (IRP) is necessary in regulating iron metabolism and maintaining iron 
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balance in an organism. When iron concentration is low in the internal environment, IRPs 
bind to the IREs in the 5’UTR of ferritin (an iron storage protein) mRNA, inhibiting its 
translation. Also, IRPs shield transferrin receptor (iron cellular uptake receptor) mRNA 
by associating with the IREs at its 3’ UTR, preventing it from degradation (Gray et. al., 
1996; Binder et. al., 1994). 
Combination between RNA-binding protein and mRNA can largely affect mRNA 
stability. Over 1/3 of mRNAs contain an AU-rich element (ARE) located in their 3’ UTR, 
which is well known as a cis-acting element responsible for mRNA turnover events. HuR 
protein is an RNA-binding protein that stabilizes mRNA through binding to ARE. The 
ARE is also a competitive binding site of mRNA destabilizing proteins, such as AUF1 
and KRP. These destabilizing proteins facilitate mRNA decay by recruiting exosome 
complex and/or exonuclease (Garneau et. al., 2007; Palanisamy et. al., 2008; Chou et. al., 
2006). Interestingly, although AUF1 mostly promotes RNA degradation, it also has the 
ability to stabilize mRNAs in some cases when it functions cooperatively with other 
proteins (Kiledjian et. al., 1997). 
As mentioned in the last section, various ribonucleases, such as XRN1, PMR1 and 
IRE1, are involved in RNA turnover pathway. XRN1 is an exonuclease that recognizes 
5’-monophosphate and cleaves decapped mRNA in all the 5’ to 3’ mRNA decay pathways. 
In endonuclease-mediated mRNA decay pathway, endonucleases including PMR1 and 
IRE1 cleave mRNAs which are being translated (Garneau et. al., 2007).  
The endogenous miRNA and the exogenous siRNA are both non-coding RNAs. In 
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RNA silencing, they recognize and bind to specific sequences located at mRNA coding 
region and lead to mRNA being sliced by RISC complexes. Targeted mRNA is 
complementary to siRNA or miRNA and forms a RNA duplex. It is then cleaved by 
Argonaute which is part of the RISC complex. The cleaved RNA is finally degraded by 
the same enzymes that takes part in general RNA decay pathways. Evidence also reveals 
that miRNA and RISC can promote mRNA decapping and repress translation initiation 
(Valencia-Sanchez et. al., 2006). 
1.3 RNA-binding proteins in the Regulation of mRNA Stability  
    RNA-binding proteins (RBPs) are a group of proteins that bind to multiple mRNAs 
either to prevent or accelerate mRNA degradation in cells. RBPs could regulate multiple 
RNA targets and different RBPs can bind their RNA targets specifically by recognition of 
RNA structure and/or sequence (Lee et. al., 2006). For example, the RNA-binding protein 
CRD-BP can bind to various oncogenic RNAs, including c-Myc, CD44 and KRAS 
mRNAs (Mahapatra et. al., 2013, King et. al., 2014, Mongroo et. al., 2011).The 
RNA-binding protein HuR shows high affinity to AU-rich element (ARE) of TNF-α 
mRNA (Chae et. al., 2009). Other RBP includes the GRE binding protein CUGBP that 
binds to GU-rich element (GRE) to inhibit viral gene expression in cells through synergy 
with U1 binding protein (Goraczniak et. al., 2008). 
1.4 Coding Region Determinant-Binding Protein (CRD-BP) 
1.4.1 Structure and Function 
The Coding Region Determinant-Binding Protein (CRD-BP, also termed IMP-1/ 
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IGF2BP1/ZBP1) is an oncofetal protein that belongs to a family of highly conserved 
RNA-binding protein called VICKZ (Mahapatra et. al., 2013, Yisraeli, 2005). It is 
believed to bind to some of its target oncogenic mRNAs and to shield mRNAs from 
degradation. (Doyle et. al., 1998). 
CRD-BP has two RNA recognition motifs (RRM) and four hnRNP K-homology 
(KH) domains. The ~ 90 amino acids long RRM consists of two subunits call RNP-1 and 
RNP-2, and each of the subunits shows a β-α-β-β-α-β topology (Yisraeli, 2005). The KH 
domain is approximate 70 amino acids long with a β-α-α-β-β-α structure, and a conserved 
GXXG loop is located between α1 and α2 of the KH domain (Valverde et. al., 2008). The 
KH domains are necessary for binding of CRD-BP. Mutations in the GXXG loop of any 
two KH domains of CRD-BP would result in reduced binding affinity to CRD-BP target 
transcripts (Barnes et. al., 2015). 
1.4.2 Roles in Cancer 
Although CRD-BP is rarely observed in normal adult cells, it is commonly found in 
fetal tissues and various tumor cells, including ovarian, colon, breast, lung, testicular and 
brain cancers (Gu et. al., 2004; Doyle et. al, 2000; Ross et. al., 2001; Kato et. al., 2007; 
Hammer et. al., 2005; Ioannidis et. al., 2004). Overexpression of CRD-BP in cells leads 
to increased potential of oncogenesis by promoting cell proliferation and up-regulate 
expression of oncogenes, suppression of cell apoptosis, as well as resistance to anticancer 
drugs. Evidence clearly indicates that CRD-BP is essential for oncogenesis and 
progression in several human cancers, through stabilization of oncogenic mRNAs which 
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include c-myc, ERK, GLI1, CD44 and MDR-1 (Vikesaa et. al., 2006; Mahapatra et. al., 
2013). In an in vitro study, CRD-BP has been shown to prevent c-myc and MDR-1 
mRNAs from endonucleolytic cleavage through shielding the coding region of mRNA 
(Sparanese and Lee, 2007).     
1.4.3 Therapeutic Approaches against CRD-BP 
Although CRD-BP is rarely observed in normal adult cells, it is over-expressed in 
fetal tissues and various tumor cells, including leukemia, colon, breast, pancreatic and 
lung cancer (Vikesaa et. al., 2006; Noubissi et. al., 2006; Gu et. al., 2008; Ross et. al., 
2001; Kato et. al., 2007; Hammer et. al., 2005; Ioannidis et. al., 2004). This suggests that 
CRD-BP is a very suitable target in cancer therapy (Leeds et. al., 1997). Disrupting the 
interaction between CRD-BP and oncogenic mRNA by specific oligonucleotides (such as 
sense- or antisense oligonucleotides against mRNA) or small molecules would constitute 
a new anti-cancer strategy, and if successful, would lead to the discovery of new groups 
of anti-cancer compounds which act through a new molecular pathway.  
Application of antisense oligonucleotide (AON) is a newly emerged anti-cancer 
therapeutic method. King et.al. (2014) designed a set of AONs against CD44 RNA to 
interrupt CRD-BP-CD44 mRNA interaction. Three of these AONs (DD4, DD7 and DD10) 
were found to specifically and effectively inhibit the binding of [32P]-labeled CD44 RNA 
fragment to CRD-BP in vitro, and the cell mRNA levels of CD44 showed a roughly 60% 
decrease by treating cells with 100 nM of DD4 or DD7. Similarly, Mehmood et. al. (2016) 
reported an effective sense oligonucleotide (namely S1 RNA) of GLI1 mRNA showing 
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inhibitory effects on CRD-BP-GLI1 RNA interaction. Around 90% inhibition of 
CRD-BP-GLI1 RNA binding was observed by adding 147 μM of [32P]-labeled S1 RNA 
in EMSA analysis. In addition, the mRNA levels of GLI1 and c-myc showed more than 
60% decrease in 3 out of 5 cancer cell lines when cells were treated with 100 nM of S1 
RNA. 
Besides, the use of CRD-BP siRNAs to knock down CRD-BP RNA and protein 
expression was also shown to be successful in several studies. Applying 20 nM of 
CRD-BP siRNA was able to knockdown CRD-BP mRNA levels by 55-85% in three 
breast cancer cell lines and two colon cancer cell lines (Mehmood et. al. 2016). Mongroo 
et. al. (2011) also reported that CRD-BP siRNA inhibited CRD-BP protein expression by 
more than 70%. Furthermore, the CRD-BP siRNA also suppressed cell proliferation, 
colony size and number in colon cancer cell lines. 
To date, there are only two studies reporting small molecule inhibitors of 
CRD-BP-RNA interaction. King et al. (2014) showed that while aminoglycoside 
neomycin was an effective inhibitor of CRD-BP-CD44 RNA interaction in vitro, its effect 
on such interaction in cells was difficult to demonstrate. This is because aminoglycosides, 
such as neomycin, are very positively charged and likely have affinity for many 
negatively charged bio-molecules such as nucleic acids in cells, leading to non-specific 
effects. Mahapatra et. al. (2013) applied a high-throughput fluorescence anisotropy 
screening method to identify specific small molecule inhibitors for CRD-BP-c-myc RNA 
interaction. They showed that 33 out of 17600 small molecules exhibited specific 
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inhibition on CRD-BP-c-myc RNA interaction in vitro and only 3 out of the 33 candidate 
inhibitors were effective in suppressing cell proliferation of CRD-BP positive cancer cell 
lines.  
1.5 KRAS 
1.5.1 Function and Roles in Cancer 
RAS genes (HRAS, NRAS and KRAS) are a well-known family of oncogenes, 
which are found frequently mutated in around 1/3 of all human cancer types. They 
function as a transforming protein in normal tissues, delivering signals from the 
extracellular environment to cells. The KRAS gene encodes a 21 kDa GTPase located on 
the cell membrane (Friday and Adjei, 2005) and has the highest mutational rate among 
the three known RAS oncogenes in all human tumor diseases (Arrington et. al., 2012; 
Bamford et. al., 2004). KRAS oncogene has proven to be a critical regulator in 
controlling cell development, proliferation, differentiation and apoptosis, and is known to 
promote colon tumor cell progression (Friday and Adjei, 2005; Arrington et. al., 2012).   
1.5.2 Therapeutic Approaches against KRAS 
Given that KRAS is highly implicated in human carcinomas, it is not surprising to 
see the development of therapeutic approaches targeting KRAS (Friday and Adjei, 2005). 
The application of AONs can result in blocked translation as well as degradation of RAS 
mRNA via RNase H-mediated RNA decay mechanism. Also, designed siRNAs can lead 
to targeted mRNA decay by catalytic activities. However, cell toxicity and the delivery of 
nucleic acid-based compounds such as AON an siRNA remains a major hurdle clinically 
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(Friday and Adjei, 2005). Therefore, researchers had started to explore other therapeutic 
methods, such as disrupting KRAS signaling pathway by inhibiting the expression of Raf 
kinase and mitogen activated protein kinase (MEK). MEK inhibitors including CI-1040, 
PD 0325901 and AZD6244 are in clinical trials for the possible treatment of breast cancer, 
colon cancer, NSCLC, or melanoma (Adjei, 2008). In addition, Dai et. al. (2015) noticed 
that tumor suppressor let-7 is able to be used as a chemosensitizer in KRAS mutated 
cancer cell lines. Let-7b effectively inhibited mutated KRAS expression, and decreased 
the IC50 of paclitaxel and gemcitabine cytotoxicity to less than half in KRAS mutant 
cancer cells. Inhibition of cell cycle progression, migration and invasion was also 
observed with the combined use of let-7 and paclitaxel/gemcitabine. Small molecules are 
now thought to be hopeful therapeutic agents and will be investigated as part of my 
research to find molecules that are capable of breaking CRD-BP-KRAS RNA interaction.   
1.5.3 KRAS mRNA and its interaction with CRD-BP 
CRD-BP binds directly to KRAS mRNA at its coding region and 3’ UTR. KRAS 
was up-regulated upon overexpression of CRD-BP, while the loss of CRD-BP was shown 
to result in the suppression of KRAS expression and inhibition of tumor cell proliferation 
and anchorage-independent growth (Mongroo et. al., 2011). When CRD-BP level was 
knocked down in cells, a protein called CYFIP2 was significantly up-regulated. Mongroo 
et. al. (2011) found that KRAS inhibition was reversed by the knockdown of CYFIP2 in 
the absence of CRD-BP. The study demonstrated that CRD-BP positively control KRAS 
expression, causing carcinogenesis potential. Also, CRD-BP level seems to be correlated 
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with KRAS level (Mongroo et. al., 2011).  
1.6 Recent Knowledge on using Oligonucleotides in Inhibiting Gene 
Expression  
    Scientists have discovered several special oligonucleotides, including AONs, siRNA 
and miRNA, which can be used to inhibit gene expression. In 1998, dsRNAs were found 
to trigger gene silencing in Caenorhabditis elegans and this phenomenon was termed 
RNA interference (RNAi) (Fire et. al., 1998). siRNA and miRNA recognize and hybridize 
with targeted mRNA via Watson/Crick base paring, leading to mRNA degradation (Jinek 
and Doudna, 2009). Let-7 miRNA is a direct suppressor of CRD-BP, and can 
down-regulate oncogenic mRNA post-transcriptionally (Mongroo et. al., 2011, Mahapatra 
et. al., 2013). In K562 leukemia cancer cells, down-regulation of CRD-BP gene 
expression by specific siRNA against CRD-BP leads to increased expression of IGF-II 
gene (Liao et. al., 2004).    
With a similar fundamental principle, the AONs have been used for more than a 
decade to trigger RNA silencing resulting in targeted RNA decay, alternative splicing or 
translation inhibition (Dean and Bennett, 2003). For instance, a significant suppression of 
breast tumor cell progression is observed after intraperitoneal injection of AON into mice 
(Lamb et. al., 2005). An apolipoprotein B AON was also shown to successfully reduce 
LDL cholesterol level in animal experiments (Crooke et. al., 2005). These and many other 
findings showed that oligonucleotide-based therapy is indeed a promising approach for 
the treatment of cancers. 
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The use of oligonucleotides to competitively inhibit specific protein-mRNA 
interactions has also been explored as a new therapeutic tool in a number of diseases. In 
an antisense RNA intracellular study, the AONs designed to be complementary to HIV 
genes can bind to regulatory and structural transcript products and repress viral genome 
replication in an early stage (Veres et. al., 1998). Examples are also found in different 
cancer studies. The AONs that target to a specific sequence in bcl-xL (an anti-apoptotic 
protein) mRNA can largely suppress bcl-xL expression in lung cancer cells (Leech et. al., 
2000). Two specific AONs are found to decrease bcl-xL and bcl-2 (an anti- apoptotic 
protein) mRNA and protein levels in malignant pleural mesothelioma, and promote cell 
apoptosis (Simões-Wüst et. al., 2002). AONs were also shown to interrupt the interaction 
between c-myc mRNA and CRD-BP, downregulate c-myc expression and inhibit cell 
proliferation (Coulis et. al., 2000). Similarly, specific AONs have been shown to inhibit 
CRD-BP-CD44 mRNA interaction and suppress CD44 mRNA expression in cells (King 
et. al., 2004).       
1.7 Recent Knowledge on using Small Molecules in Inhibiting Gene 
Expression   
There is now ample evidence showing the ability of small molecules to specifically 
interrupt protein-RNA binding. For example, mitoxantrone can disrupt HuR-TNF-α RNA 
interaction. HuR RNA-binding protein stabilizes TNFα mRNA through attachment to the 
AREs located at the mRNA 3’UTR (D'Agostino et. al., 2013). Quercetin is another potent 
small compound which selectively disrupt the interaction between HuR protein and ARE 
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in TNFα mRNA (Chae et. al., 2009). In assessing HIV-1 Rev-RRE binding, small 
molecules including Lambda-[Ru(bpy)(2)eilatin]2+ and Delta-[Ru(bpy)(2)eilatin]2+ were 
shown to be efficient inhibitors of HIV-1-Rev-RRE binding as well as in HeLa plaque 
formation, since their structures are recognized as the RRE binding ligands (Luedtke and 
Tor, 2003). Small molecule antibiotics including neomycin, paramomycin, kanamycin 
and streptomycin were all shown to be effective in blocking CRD-BP-CD44 mRNA 
interaction in vitro. Unfortunately, such inhibition was proved to be non-specific in cells 
(King et. al., 2014). 
1.8 Goals of Research 
The primary goals of my research are to find compounds, especially small organic 
molecules, which can inhibit the CRD-BP-KRAS mRNA interaction in vitro, and then 
assess them for their ability to inhibit KRAS expression in colon cancer cells. 
To achieve my primary goals, the following four specific steps were taken: (i) I used 
the electrophoretic mobility shift assay (EMSA) to assess a panel of specific 
oligonucleotides for their ability to disrupt CRD-BP-KRAS RNA interaction, (ii) I 
performed a series of experiments to validate the fluorescent polarization (FP) method to 
study CRD-BP-RNA interaction, (iii) using the established FP method, I screened a 
library of small molecules for their ability to inhibit CRD-BP-KRAS RNA interaction, 
and (iv) I assessed candidate oligonucleotides and small molecules for their ability to 
inhibit KRAS and CRD-BP expression in colon cancer cell lines. 
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CHAPTER 2 To Identify Small Molecule Inhibitors of 
CRD-BP-KRAS RNA Interaction  
The goal of this chapter is to identify inhibitors of CRD-BP-KRAS RNA interaction 
in vitro. The electrophoretic mobility shift assay (EMSA) was used to assess the potential 
inhibitory effect of 8 reverse oligonucleotides (RONs) designed against KRAS transcript 
on the CRD-BP-KRAS RNA interaction. RONs are direct reverse sequences of RNA 
where AONs are reverse and complementary sequences. By applying [32P]-labeled KRAS 
RNA, I could determine whether CRD-BP-KRAS RNA interaction is inhibited by these 
RONs. This can be achieved by observing the position of the isotope-labeled free RNA 
and its complex.  
In this Chapter, I also describe the establishment of the fluorescence polarization (FP) 
method to study CRD-BP-KRAS RNA interaction. I first show the proof-of-principle that 
the FP method can be reliably and reproducibly use to study CRD-BP-KRAS RNA 
interaction. The established FP assay was then used to screen a library of small molecules 
for their ability to inhibit CRD-BP-KRAS RNA interaction. 
2.1 Methodology - Assessing reverse oligonucleotides (RONs) for 
their ability to inhibit CRD-BP-KRAS RNA interaction 
A previous study in Dr. Lee’s lab has shown that some specific sense 
oligonucleotides were capable of inhibiting CRD-BP-GLI1 RNA interaction (Mehmood 
et. al., 2016). To this end, I assessed a panel of 8 specific RONs against KRAS RNA for 
their ability to inhibit CRD-BP-KRAS RNA interaction by applying the EMSA. The 8 
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RONs (see Table 2.1) were purchased from Integrated DNA Technologies, Iowa, USA.  
Table 2.1 Sequences of RONs 
RONs Sequences 
RON_JW1 
RON_JW2 
RON_JW3 
RON_JW4 
RON_JW5 
RON_JW6 
RON_JW7 
RON_JW8 
5’-TGG TGT TCA AAT ATA AGT CAG TA-3’ 
5’-ACG GAT GCG GTG GTC GAG GTT GA-3’ 
5’-ATC GAC ATA GCA GTT CCG TGA GA-3’ 
5’-AGC AGG TGT TTT ACT AAG ACT TA-3’ 
5’-TTA GGA GAT AAC AAC CTA GTA TA-3’ 
5’-TTA ATG ATG AAC GAA GGA CAT CC-3’ 
5’-AGG TTC TCT GTC CAA AGA GGT AG-3’ 
5’-AGT ACT GGA CGA CAC AGC TCT TAT-3’ 
2.1.1 Protein purification and quantification 
Recombinant CRD-BP protein was generated in collaboration with Mr. Sebastian 
Mackedenski. The pET28b-CRD-BP plasmid DNA was a gift from Dr. Jeffrey Ross, 
University of Wisconsin.  The plasmid contains a kanamycin resistance gene as well as a 
full length wild-type mouse CRD-BP coding sequence flanked by an amino terminus 
FLAG epitope and C-terminus 6 x His-tag. The recombinant protein was generated and 
purified using the protocol described below. 
One hundred μL of E.coli BL21 (DE3) cells were stored at – 80°C and thaw on ice. 
One μL of plasmid DNA (~100ng) was added to the BL21 competent cells and kept on 
ice for 25 minutes. Cells were then heat shocked at 42°C for 90 seconds. Three hundred 
μL of lysogeny broth (LB) was added to the cells which was followed by incubation at 
37°C for 30 minutes. Cells were then spread on a LB-Kan (25 μg/mL of kanamycin 
sulfate) agar plate. After the plate dried, it was covered by lid and sealed. The plate was 
placed in a 37°C incubator overnight in an up-side down position. The next day, about 20 
colonies were picked from the plate using a pipette tip. These colonies were then swirled 
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in a 250 mL flask with 100 mL LB broth and 100 μL kanamycin sulfate (25 μg/mL). After 
cells were grown in a shaker for around 3 hours, broth was transferred to a 3 L flask and 
mixed with 900 mL LB broth and 900 μL kanamycin sulfate (25 μg/mL). Cells were 
grown on shaker again until an OD600 of 0.5 was reached, followed by the addition of 1 
mL of 1M IPTG. After shaking for additional 6 hours, cells were spun at 3000 g at 4 °C 
for 15 minutes and the pellets frozen at – 80 °C overnight.  
On the third day, bacterial pellets were thawed on ice for 15 minutes and 
resuspended in 12 mL buffer B. Cell lysate was collected in a 50 mL falcon tube and was 
waved (setting 4) on ice for 1 hour till solution became semi-translucent. The cell lysate 
was then spun at 13,200 g at 4°C for 30 minutes; meanwhile, 2 mL of 
nickel-nitrilotriacetic acid (Ni-NTA) agarose beads (Qiagen, Hilden, Germany) solution 
was added in a mini-column (Qiagen, Hilden, Germany) and was sequentially washed 
with 5 mL H2O and 5 mL buffer B. The column was caped and 1.5 mL of buffer B was 
added to cover the resin. After centrifugation of cell lysate, supernatant was filtered (0.45 
um) with a syringe into a new 50 mL falcon tube. The contents of the column were slurry 
and mixed with the filtered supernatant and was waved (setting 3) for another 1 hour on 
ice. After that, lysate-resin mixture was loaded onto the column and ready of protein 
purification. The mini-column was sequentially washed with 5 mL buffer B, 5 mL buffer 
C, and 5 mL buffer D. The column was then washed with 12 mL buffer E, and 0.5 mL of 
eluted solution was collected into 24 tubes. This was followed by 12 mL buffer F, and 
similarly 0.5 mL of eluted solution was collected into 24 tubes. All the fractions were 
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stored at – 80°C. Column was then washed with 6 mL 0.5 M NaOH followed by 10 mL 
H2O. The washed mini-column was capped and stored in 2 mL of 30 % ethanol in the 
fridge. 
To determine protein purification, SDS-PAGE analysis was performed on 18 
fractions chosen from eluted fraction E and F. Chosen fractions were odd number tubes 
from fraction E3 to F13. Ten % polyacrylamide denaturing gels were prepared as 
according to the recipe shown in Table 2.2. 
Table 2.2 Reagents used for 10% polyacrylamide denaturing gel 
Lower gel mix Volume  (4 mL) 
30% acylamide + 0.8%bis 1.33 mL 
4x lower gel buffer 1 mL 
Water 1.67 mL 
TEMED 2.4 μL   
20% APS 8 μL  
Upper gel mix Volume (2.7 mL) 
30% acylamide + 0.8%bis 0.48 mL 
4x upper gel buffer 0.45 mL 
Water 1.77 mL 
TEMED 3 μL  
20% APS 7.5 μL  
Sixteen μL of each protein was mixed with 4 μL of 5 x SDS sample buffer dye 
(containing 5% β-mercaptoethanol) prior to 10 minutes of boiling. Electrophoresis was 
performed at 160 volts for 55 minutes followed by gel staining with Coomasie blue on a 
waver for 30 minutes. Gel was then destained with destain solution (1 L destain solution 
consists of 50 mL methanol, 70 mL acetic acid and 880 mL H2O) on waver for 40 minutes, 
and was visualized and analyzed by MultiImage® light cabinet and AlphaView software 
(Alpha Innotech, California, USA). CRD-BP protein fractions which have relatively good 
purity were selected for dialysis. Since protein was stored in 8 M urea, the refolding step 
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for recovering protein activity is required. One hundred μL of protein was first transferred 
to a 3500-molecular weight cut-off Slide-A-Lyzer® MINI dialysis unit (Thermo 
Scientific, Illinois, USA). The dialysis unit was then placed into 50 mL dialysis buffer A 
(see Table 2.3) for 24 hours in cold room. Following an overnight dialysis, the dialysis 
unit was placed into a 50 mL dialysis buffer B (see Table 2.3) for 4 hours followed by 
another 4 hour dialysis in 200 mL dialysis buffer B. Dialyzed protein was stored in 4 °C 
for a maximum of 2 weeks. 
Table 2.3 Reagents used for Dialysis buffers 
Dialysis buffer A Volume (50 mL) 
5 M NaCl 2 mL 
1 M Tris-HCl (pH8) 1 mL 
100% glycerol 5 mL 
Urea 6 g 
10% triton-X 100 50 μL  
0.2 M GSH (reduced) 0.25 mL  
0.1 M GSSG (oxidized) 50 μL  
ddH2O to 50 mL 
pH 7.4  
Dialysis buffer B Volume (250 mL) 
5 M NaCl 10 mL 
1 M Tris-HCl (pH8) 5 mL 
100% glycerol 25 mL 
10% triton-X 100 250 μL  
ddH2O to 250 mL 
pH 7.4  
BCA assay was performed to determine protein concentration. The procedure used 
was according to the instructions from PierceTM BCA protein assay kit (Thermo scientific, 
Illinois, USA). Briefly, albumin standard stock (2 mg/mL) was first diluted with dialysis 
buffer B into a set of concentrations (75 mg/mL, 125 mg/mL, 250 mg/mL, 500 mg/mL, 
750 mg/mL, 1000 mg/mL and 1500 mg/mL). Working reagent was prepared by mixing 50 
parts of BCA reagent A and 1 part of BCA reagent B. Twenty μL of each sample or 
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standard was added to 200 μL of working reagent in a 96-well plate (Sarstedt, Nümbrecht, 
Germany) and plate was then shaken on a plate shaker for 30 seconds prior to incubation 
at 37°C for 30 minutes. Following incubation, absorbance was measured at 562 nm using 
Synergy 2 multi-mode reader (BioTek, Vermont, USA) and analyzed with Gen5™ 
software (BioTek, Vermont, USA).  
2.1.2 [32P]-labeled KRAS RNA in vitro transcription   
KRAS RNA was transcribed in the presence of [32P]-UTP and then diluted to 25,000 
cpm/μL for use in electrophoretic mobility shift assay reaction. The [32P]-labeled KRAS 
RNA was prepared by Mr. Sebastian Mackedenski using the following protocol. The 
reagents shown in Table 2.4 were used for in-vitro transcription (IVT) reactions. 
Table 2.4 Reagents used for IVT reactions 
IVT reaction mixture Volume (20 μL ) 
5x transcription buffer 4 μL  
100 mM DTT 2 μL  
40 U/μL  RNasin 1 μL  
10 mM ATP 1 μL  
10 mM CTP 1 μL  
10 mM GTP 1 μL  
100 μM UTP 1 μL  
DNA template 600 ng 
[32P]-UTP 2.5 μL  
15 U/ μL T7 RNA polymerase 1 μL  
DEPC water to 20 μL  
All the reagents were briefly spun down to mix and were incubated at 37°C for 1 
hour. Ten μL 1 U/μL RNase-free DNase was added followed by10 minutes incubation at 
37°C incubation. Ten μL urea loading dye (9 M urea, 0.01% bromophenol blue, 0.01% 
xylene cyanol, 0.01% phenol) was added to stop the enzymatic reaction prior to RNA gel 
purification. RNA mixture was run on an 8% polyacrylamide (29:1 bis:acrylamide) 
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denaturing gel (7 M urea) at 25 mA for 1 hour in 0.5 x TBE buffer. RNA band was sliced 
after gel visualization, and dissolved in 400 μL of water at 70°C for 10 minutes in a 
screwcap tube. RNA solution was loaded onto Performa DTR gel filtration cartridges 
(Edge Bio, Maryland, USA) prior to centrifugation at 3000 g for 3 minutes. The 400 μL 
of filtered RNA was mixed with 1400 μL 100% ethanol and 200 μL 10 X glycogen (0.2 
mg/mL glycogen in 3 M sodium acetate, pH 5.2), followed by precipitation at – 20°C 
overnight. The mixture was then spun at 12,000 g for 20 minutes. Pellet was kept and 
washed with 200 μL 70% ethanol for 2 minutes, followed by ethanol removal. The dried 
pellet was then resuspended in 20 μL DEPC water. 
2.1.3 Electrophoretic mobility shift assay competition assay  
The competitive electrophoretic mobility shift assay (EMSA) was performed to 
assess the effectiveness of the 8 KRAS RONs to compete with the [32P]-labeled KRAS 
RNA in binding to CRD-BP. The RONs were assessed with 10 X and 50 X molar excess 
of the [32P]-labeled KRAS RNA. The same molar excess of the unlabeled KRAS RNA 
were used as positive controls. Reagents for EMSA reaction are shown in Table 2.5. 
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Table 2.5 Reagents for EMSA reaction 
EMSA binding buffer Volume (1 mL) 
1 M Tris-Cl ( pH 7.4) 50 μL  
0.5 M EDTA ( pH 8.0) 25 μL  
100 mM DTT 100 μL  
50% Glycerol 500 μL  
10% Triton-X 100 1 μL  
ddH2O 324 μL  
EMSA reaction reagent Volume (17 μL ) Final concentration 
EMSA binding buffer 4 μL   
Baker’s yeast tRNA (25 mg/ mL) 1 μL   
BSA (10 mg/ mL) 1 μL   
RNasin (40 U/ μL ) 1 μL   
CRD-BP  7 μL  217 nM 
[32P]-labeled KRAS RNA 2 μL  118 pM 
Competitors  1 μL  1.18 nM and 5.9 nM 
EMSA binding buffer was divided into aliquots and stored at –20 °C. The 
[32P]-labeled KRAS RNA was refolded by heating to 55 °C for 5 minutes followed by 
cooling to room temperature for 7 minutes. All the reagents for EMSA reaction were 
added on the side of microcentrifuge tube and spun down in 1.5 mL centrifuge tubes to 
start reactions. The mixture was then incubated at 35°C for 10 minutes followed by 
incubation on ice for 5 minutes. Such warm-cool incubation step was repeated one more 
time to complete the binding reaction. Two μL of EMSA loading dye was added to each 
centrifuge tube prior to loading onto an 8% polyacrylamide gel (29:1 bis:acrylamide) 
non-denaturing gel in 0.5 x TBE running buffer. The gel was subjected to electrophoresis 
for 55 minutes at 25 mA. EMSA gels were typically exposed onto phosphor screens 
overnight at -80°C and images visualized using a Cyclone Storage Phosphor Imager 
system (Packard Instrument Company, Connecticut, USA) using Optiquant software 
version 4.0 (Packard Instrument Company, Connecticut, USA).  
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2.2 Methodology - Screening small molecule inhibitors for ability to 
inhibit CRD-BP-KRAS RNA interaction 
    The fluorescence polarization (FP) method must first be established, in order to 
conveniently study the CRD-BP-KRAS RNA interaction and to screen a library of small 
molecule for their ability to inhibit CRD-BP-KRAS RNA interaction. The library of small 
molecules consisted of 217 dispiro pyrrolizidine/indanone derivatives were then assessed 
by the FP method to identify potential inhibitors of CRD-BP-KRAS RNA interaction. 
2.2.1 Establishing the Fluorescence Polarization method to study CRD-BP-KRAS 
RNA interaction 
At the outset of this study, Dr. Lee’s lab has mapped the smallest region of both 
CD44 (King et. al., 2014) and KRAS (Sebastian Mackedenski, unpublished results) 
RNAs that are still capable of binding to CRD-BP. Based on these previous studies, a 
39-nt fluorescent-labeled CD44 (FL-CD44) RNA (5’- AAA UUA GGG CCC AAU UAA 
UAA UCA GCA AGA AUU UGA UCG /Fl/ -3’ ) (Thermo Scientific, Illinois, USA) and a 
44-nt fluorescent-labeled KRAS (FL-KRAS) RNA (5’- AUG GAG AAA CCU GUC 
UCU UGG AUA UUC UCG ACA CAG CAG GUC AU/ 36FAM/ -3’) (Integrated DNA 
Technologies, Iowa, USA) were commercially synthesized. In addition, Dr. Lee’s Lab has 
designed eight antisense oligonucleotides (AONs) against KRAS mRNA and found two 
AONs that could block CRD-BP-KRAS mRNA binding in vitro (Sebastian Mackedenski, 
unpublished data). One of the two inhibitors, SM7 (5’-UCC AAG AGA CAG GUU UCU 
CCA UC-3’) (Integrated DNA Technologies, Iowa, USA), was used as a positive control 
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in my experiments described in this thesis. SM2 (5’-UGC CUA CGC CAC CAG CUC 
CAA CU-3’) (Integrated DNA Technologies, Iowa, USA) which had no effect on 
CRD-BP-KRAS RNA interaction, was chosen as a negative control in the FP assay. And 
the concentration of both AONs used in the FP assay is 500 nM. 
Wild-type (WT) CRD-BP was purified and quantified using the protocols described 
in section 2.1.1 and its corresponding recombinant KH variants were provided by other 
member in the Lee Lab. The CRD-BP variants, KH1-2, KH3 and KH3-4, harbor single or 
double point mutations in the first glycine of the GXXG conserved motif located in each 
KH domain of CRD-BP (Barnes et. al., 2015). Structures of CRD-BP and KH variants are 
shown in Figure 2.1.  
 
Figure 2.1 Schematic diagram of CRD-BP. CRD-BP consists of 2 RNA recognition 
motifs (RRMs) and 4 K homology (KH) domains. Point mutation occurs in GXXG motif 
on KH domains. KH1-2 harbors a point mutation on KH1 and KH2 domains respectively. 
KH3 harbors a point mutation on KH3 domain. KH3-4 harbors a point mutation on KH3 
and KH4 domains respectively. 
Several concentrations of fluorescent-labeled RNAs were tested on a fixed 
concentration of CRD-BP in the FP assay to determine the optimal assay concentration. 
The KH variants of CRD-BP have been shown to have deficiency in binding to KRAS 
(Sebastian Mackedenski, unpublished observations) and/or CD44 RNAs (Barnes et. al., 
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2015) as determined using the [32P]-labeled EMSA. To assess the specificity of 
CRD-BP-RNA binding and to determine the suitable working concentration for small 
molecule screening, the binding profile of CRD-BP wild-type and its KH variants were 
studied using the FP assay. 
CRD-BP WT and KH variants were diluted to designated concentrations with 
dialysis buffer B. The concentrations of CRD-BP WT and KH variants used in 
experiments were described here. 
Table 2.6 Reagents used for FP assay 
FP binding buffer Volume (1 mL) 
1 M Tris-Cl ( pH7.4) 50 μL  
0.5 M EDTA ( pH8.0) 25 μL  
50 % Glycerol 500 μL  
10 % Triton-X 100 1 μL  
ddH2O 424 μL  
FP assay reagent Volume (19 μL ) Final concentration 
FP binding buffer 4 μL   
CRD-BP  7 μL  0-1000 nM 
fluorescent-labeled RNA 5 μL  10 nM 
ddH2O 3 μL   
All the reagents (see Table 2.6) for FP assay were pipetted into a 384 Microfluor 1 
Microtiter® plate (Thermo Electron, Massachusetts, USA) and incubated at 37°C for 10 
minutes followed by 5 minute on ice bath. Reaction tubes were then incubated again at 
37°C for 10 minutes and 5 minutes on ice bath prior to plate reading. Plate was read 
(485/20 excitation light, 528/20 emission light) using Synergy 2 multi-mode reader 
(BioTek, Vermont, USA) and analyzed with Gen5™ software (BioTek, Vermont, USA).   
2.2.2 Screening a small molecule library for ability to inhibit CRD-BP-KRAS RNA 
interaction 
After the establishment of the FP method, I proceeded to screen the library of small 
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molecules for their ability to disrupt CRD-BP-KRAS RNA interaction, namely by 
measuring any decrease in FP units as an indicator of disruption of CRD-BP-RNA 
interaction. The library of small molecules that I assessed consists of 217 dispiro 
pyrrolizidine/indanone derivatives. These were obtained from the University Sains 
Malaysia. Dr. Lee’s lab has previously identified two antisense oligonucleotides, SM7 and 
SM6, which are effective inhibitors of CRD-BP-KRAS RNA interaction (Sebastian 
Mackedenski, unpublished results), while SM2 antisense oligonucleotide had no effect. 
Therefore, I used these antisense oligonucleotides as controls in my screening 
experiments. Since the small molecules were resuspended in DMSO, I also assessed 
various concentrations of DMSO on FP measurements to determine the concentration at 
which DMSO has effect on FP measurements. Each small molecule was assessed with a 
fixed concentration during the primary screening process.  
Table 2.7 Reagents used for small molecule library screening 
FP assay reagent Volume (19 μL ) Final concentration 
FP binding buffer 4 μL   
CRD-BP  7 μL  500 nM 
fluorescent-labeled RNA 2 μL  10 nM 
small molecule 4 μL  100 μM 
ddH2O 2 μL   
    The contents in FP binding buffer are shown in Table 2.6. All reagents (Table 2.7) 
for library screening were first mixed together to make a master mix, except for the small 
molecules. Small molecules were then pipetted into a 384 Microfluor 1 Microtiter® plate 
(Thermo Electron, Massachusetts, USA) followed by addition of the master mix. 
Incubation steps for CRD-BP-KRAS RNA binding reaction followed the same procedure 
as those described in section 2.2.1.  
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Dose-dependent assays of small molecule inhibitors were performed after candidate 
inhibitors were identified from the primary screening step. Selected small molecules were 
diluted from 0 to 100 μM with DMSO and incubated with fixed concentration of KRAS 
RNA and CRD-BP WT. 
2.3 Results and Discussion 
2.3.1 EMSA Competition assay 
The eight RONs (Table 2.1), designed by Dr. Lee, are reverse oligonucleotides 
against the KRAS transcript nts 1-186. It was previously shown that sense 
oligonucleotides against GLI1 mRNA could inhibit interaction between CRD-BP and the 
truncated GLI1 mRNA (Mehmood et. al., 2016). Both sense oligonucleotide and RON 
were postulated to imitate KRAS mRNA secondary structures and be recognized by 
CRD-BP, thereby competing with KRAS transcript in binding to CRD-BP. Therefore, it 
would be of interest to assess if RONs against KRAS mRNA can inhibit CRD-BP-KRAS 
RNA interaction. Because RON is a direct reverse sequence of an RNA, the nucleotides 
that account for hairpin structures are still the same. The KRAS RNA substrate used in 
the EMSA was a truncated binding region corresponding to nts 93-185 that still has 
affinity for CRD-BP (Sebastian Mackedenski, unpublished data). The unlabeled KRAS 
RNA used as a positive control competitor RNA has the same sequence as the 
[32P]-labeled KRAS RNA nts 93-185.  
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Figure 2.2 Assessing KRAS RONs for ability to compete with the [32P]-labeled KRAS 
RNA nts 93-185 for binding to CRD-BP. 118 pM of [32P]-labeled KRAS RNA (lane1) 
was mostly gel shifted by 217 nM of CRD-BP (lane 2). Unlabeled KRAS mRNA was 10 
molar-fold (1.18 nM) and 50 molar-fold (5.9 nM) of [32P]-labeled KRAS RNA (lanes 3 
and 4). RON competitors (lanes 5-20) were assessed with 10 molar-fold (1.18 nM) and 50 
molar-fold (5.9 nM) excess of the [32P]-labeled KRAS RNA. The results shown is a 
representative of three separate experiments (n=3). 
As shown in Figure 2.2, at 10- and 50-fold molar excess none of the RONs showed 
any ability to block the binding of CRD-BP to [32P]-labeled KRAS RNA (lanes 5-20). 
This suggests that RONs of KRAS did not compete with [32P]-labeled KRAS RNA for 
binding to CRD-BP. The length of each RON is 23 nts (except RON_JW8 is 24 nts) and it 
is possible that larger sized RONs against KRAS mRNA are required to obtain sufficient 
thermodynamic free energy to form and mimic the secondary structure of KRAS mRNA. 
Alternatively, the differences between the KRAS and CD44 RONs could be due to the 
differences in the binding of these transcripts to CRD-BP (Sebastian Mackedenski, 
unpublished observation).   
2.3.2 Binding profiles of WT CRD-BP and variants 
A previous study on CRD-BP KH variants showed that any double point mutations 
on CRD-BP, except KH3-4, lost their binding affinity for CD44 RNA, while single 
point-mutated CRD-BP maintained the RNA binding ability (Barnes et. al., 2015). To 
Bound 
RNA 
Unbound 
RNA 
Molar fold 
   CRD-BP    KRAS    RON 1     RON 2     RON 3     RON 4    RON 5    RON 6     RON 7    RON 8 
0  217 nM  10x   50x   10x   50x   10x  50x    10x   50x   10x   50x  10x   50x   10x   50x  10x   50x    10x   50x 
1   2    3     4    5     6    7    8    9    10   11    12   13   14   15   16   17   18    19  20 
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validate the FP assay for studying CRD-BP-RNA interaction, the KRAS and CD44 RNA 
binding curves of CRD-BP variants and WT-CRD-BP were compared. The FP results are 
shown in Figure 2.3. 
 
Figure 2.3 The binding profiles of WT CRD-BP and its variants with KRAS RNA (A, B, 
C) or CD44 RNA (D, E, F) as determined using fluorescence polarization. Ten nM of 
fluorescently labeled KRAS RNA or CD44 were used. Results shown were based on three 
separate experiments (n=3). Error bars indicate S.E.M. 
The binding affinity of CRD-BP for its target RNA was affected by point mutations 
in the KH domains, although the effect on binding to different RNAs by each KH 
mutation was different (Barnes et al., 2015). In agreement with the in vitro EMSA results 
(Barnes et. al., 2015), KH1-2 variant displayed completely abrogated binding ability for 
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both KRAS and CD44 RNAs, while KH3 and KH3-4 variants showed binding but 
relatively weaker than that of the WT CRD-BP. Overall, the FP assay displayed results 
which are very similar to that of EMSA (Barnes et al., 2015), indicating that the FP assay 
is a valid method for studying CRD-BP-RNA interaction. 
2.3.3 Primary screening of a small molecule library 
    Upon establishing the FP method for studying CRD-BP-RNA interaction, I 
proceeded to use the FP assay to screen a small molecule library to find potential 
inhibitors of the CRD-BP-KRAS RNA interaction. Any decrease in fluorescence 
anisotropy (FA) value (fluorescence polarization units) would indicate the extent of 
dissociation of the KRAS RNA probe from CRD-BP, and suggests a candidate small 
molecule inhibitor of CRD-BP-KRAS RNA binding.  
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Figure 2.4 Primary screening of small molecules unbc1-100. FA value of each small 
molecule was compared to the DMSO control expressed as 1.0 and presented as bound 
ratio. Each reaction contains 0.4% DMSO. Final concentration of each small molecule 
was 200 μM if not indicated. Final concentration of unbc2, unbc10, unbc14 and unbc19 
was 1 mM; final concentration of unbc3 was 440 μM; final concentration of unbc7 and 
unbc16 was 1.67 mM; final concentration of unbc9 was 910 nM; final concentration of 
unbc20 was 800 μM; final concentration of unbc21 and unbc24 was 1.25 mM; final 
concentration of unbc53 and unbc54 was 500 μM; final concentration of unbc60, unbc86 
and unbc100 was 400 μM. unbc4, unbc13 and unbc30 were insoluble in DMSO and were 
not tested. Unbc2, unbc5, unbc7, unbc20, unbc74, unbc76-78, unbc80 were 
autofluorescent. Asterisk indicates autofluorescent small molecules. Ten nM of 
fluorescent-labeled KRAS RNA and 500 nM WT CRD-BP were used. Result shown is 
from one experiments (n=1), except results for SM7 were based on thirty experiments 
(n=30). 
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Figure 2.5 Primary screening of small molecules unbc101-217. FA value of each small 
molecule was compared to the DMSO control expressed as 1.0 and presented as bound 
ratio. One hundred μM of each small molecule was dissolved in DMSO to a final 
concentration of 5% DMSO. Unbc128, unbc137-141, unbc144-151, unbc153 were 
autofluorescent. unbc154, unbc159, unbc161-164, unbc166 were also autofluorescent and 
were not tested. Ten nM of fluorescent-labeled KRAS RNA and 500 nM WT CRD-BP 
were used. Asterisk indicates autofluorescent small molecules. Result shown is from one 
experiments (n=1), except results for SM7 were based on thirty experiments (n=30). 
There are some compounds that have a bound ratio above 1.0. Fifty-seven 
compounds have a bound ratio >1.0 and ≤ 1.2, and five compounds have a bound ratio > 
1.2 (data not shown). Based on the primary screening efforts, three potential candidates 
 39 
 
were identified: unbc6, unbc143 and unbc152, whose bound ratio was less than 0.8 
(Figure 2.4 and Figure 2.5). There were other small molecules which showed slight 
inhibitory effect (0.8 < bound ratio < 1.0), but they were not as potent as the three 
candidates and hence they were not studied further.   
There are some autofluorescent molecules that also showing a significant reduced 
bound ratio (Figure 2.5). However, since the autofluorescence from these small molecules 
would disrupt the signal detector in FP assay, I could not tell whether the reduced bound 
ratio is from the inhibition effect in CRD-BP-KRAS RNA binding or not. Therefore, I 
would not make any conclusion for these autofluorescent small molecules in this thesis. 
2.3.4 Secondary screening: dose-dependent assay of the candidate inhibitors  
Dose-dependent experiments of the three candidate inhibitors were accomplished to 
confirm their inhibitory effect and to obtain the inhibition curve of CRD-BP-KRAS RNA 
binding. Concentrations of the small molecules used ranges from 0 to 100 μM. 
 
Figure 2.6 Dose-dependent FP assay of unbc6. Ten nM KRAS mRNA and 500 nM WT 
CRD-BP were used. Results shown were based on three separate experiments (n=3). 
Error bars indicate S.E.M. 
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Figure 2.7 Comparing the inhibitory effects of two batches of unbc6 samples. FA values 
of unbc6-treated samples were normalized to those of DMSO and presented as bound 
ratio. Small molecules were dissolved in 5% DMSO. 10 nM KRAS mRNA and 500 nM 
WT were used. Results shown were based on three separate experiments (n=3). Error bars 
indicate S.E.M. 
Initial results of unbc6 show obvious inhibitory effect in CRD-BP-KRAS RNA 
interaction (Figure 2.6). However, a new batch of unbc6 was not able to inhibit the 
CRD-BP-KRAS RNA binding (Figure 2.7). Based on the mass spectrometry analysis 
performed by our collaborator at the University Sains Malaysia (data not shown), the 
original batch of unbc6 was degraded into 6 distinct products. The inhibitory effect of 
unbc6 was not from the compound itself, but could be due to one of its degraded products 
or from the cooperation of more than one of these degraded products. Another possibility 
is that one or more of degraded products are autofluorescent and interfered with the FP 
reading. Neither the starting material nor the intermediate in unbc6 synthesis had any 
inhibitory effect on the CRD-BP-KRAS mRNA interaction (data not shown). 
Unfortunately, due to insufficient materials for further chemical analysis, the identity of 
the degraded products of original unbc6 remains unknown. Therefore, I focused my 
efforts on the other two candidate inhibitors, unbc143 and unbc152. 
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Figure 2.8 Dose-dependent FP assays of unbc143 and unbc152. Unbc142 was used as a 
negative control. 10 nM KRAS mRNA and 500 nM WT CRD-BP were used. Results 
shown were based on three separate experiments (n=3). Error bars indicate S.E.M. 
As shown in Figure 2.8, new batches of unbc143 and unbc152 showed reproducible 
inhibitory effect on CRD-BP-KRAS RNA interaction in vitro based on the FP assay. 
Unbc143 moderately reduced the bound ratio of CRD-BP-KRAS RNA to 80% at 100 μM, 
while at the same concentration unbc152 suppressed bound ratio to less than 60%. In 
conclusion, I have successfully identified two small molecules, unbc143 and unbc152, as 
inhibitors of CRD-BP-KRAS RNA interaction in vitro.  
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CHAPTER 3 Assessing the inhibitors of 
CRD-BP-KRAS RNA interaction on KRAS gene 
expression in colon cancer cells 
At the outset of this research using the method of chemical cross-linking coupled to 
immunoprecipitation, it was previously demonstrated that CRD-BP can physically 
interact with KRAS mRNA at both the coding region and 3’UTR (Mongroo et al., 2011). 
The authors further showed that knockdown of CRD-BP in SW480 colon cancer cells led 
to decreased KRAS protein expression, while over-expression of CRD-BP led to 
increased KRAS protein expression in LIM2405 colon cancer cells (Mongroo et al., 
2011). The concomitant changes in CRD-BP and KRAS protein expression suggest that 
CRD-BP can control the expression of KRAS in colon cancer cells. It was postulated that 
CRD-BP binds to KRAS mRNA to protect the transcript from rapid decay thereby leading 
to increased KRAS protein levels.  
Dr. Lee’s lab has recently shown that antisense oligonucleotides (AONs) SM7 and 
SM6 were effective inhibitors of CRD-BP-KRAS mRNA interaction in vitro (Sebastian 
Mackedenski, unpublished observations). In Chapter 2 of this thesis, I successfully used 
fluorescence polarization method to identify two small molecules, unbc143 and unbc152, 
which were capable of inhibiting CRD-BP-KRAS mRNA interaction. In this Chapter, I 
used quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot 
analysis to assess the effect of 2’-O-methyl version of SM6 and SM7 antisense 
oligonucleotides, as well as unbc143 and 152, for their abilities to influence KRAS RNA 
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gene expression in three human colon cancer cells.  
3.1 Methodology – Detecting CRD-BP and KRAS mRNA levels in 
cells 
Using the qRT-PCR method, I first treated SW480 colon cancer cells with CRD-BP 
siRNAs (Table 3.1) to determine if CRD-BP can truly influence KRAS expression. After 
the successful establishment of the relationship between CRD-BP and KRAS in SW480 
cells, I then assessed the effect of SM6, SM7, unbc143 and unbc152 on gene expression 
in the cells. For the AON SM6 and SM7 experiments, I used SM2, the AON that did not 
have inhibitory effect on CRD-BP-KRAS mRNA interaction in vitro as the negative 
control. All the AONs were assessed at a concentration previously shown to be effective 
in inhibiting gene expression (King et. al., 2014). Small molecule candidates, unbc143 
and unbc152, were assessed using 3 different concentrations. 
Table 3.1 Sequences of CRD-BP siRNAs 
CRD-BP 
siRNAs  
Duplex sequences References 
CRD-BP 
siRNA1 
5’-CCU GGC UGC UGU AGG UCU UUU CC-3’ 
3’-GGA CCG ACG ACA UCC AGA AAA GG-5’ 
Ioannidis et. 
al., 2005 
CRD-BP 
siRNA2 
  5’-GGA GGA GAA CUU CUU UGG UCC CAA G-3’ 
3’UU CCU CCU CUU GAA GAA ACC AGG GUU C-5’ 
Kato et. al., 
2007 
3.1.1 Cell preparation and total RNA extraction 
Colon cancer cell line SW480, HT29 and CaCO2 (all from American Type Culture 
Collection, Virginia, USA) were stored in liquid nitrogen medium containing 5% DMSO. 
Cells were rapidly thawed in 37°C water bath for 2 minutes. Cells were transferred into a 
25 cm2 tissue culture flask and top up to 10 mL with the medium EMEM (BioWhittaker, 
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Cologne, Germany). Cells were cultured in the direct heat CO2 incubator (37°C, 5% CO2) 
until 90% confluent, and then were split into two to four 75 cm2 tissue culture flasks. 
When cells were 90% confluent, cells were first washed with 3 mL of PBS 
(BioWhittaker, Cologne, Germany) before trypsinization using 2 mL 0.25% 
trypsin-EDTA in 37 °C incubator for 2-5 minutes. After all the cells were detached from 
the culture flask, trypsin was inactivated with 18 mL EMEM (with 10% serum). Twenty 
μL resuspended cells were then mixed with 20 μL of trypan blue prior cell counting using 
the Bright-Line Hemacytometer (Hausser Scientific, Pennsylvania, USA). Cells were 
plated onto 6-well plates with a cell density of 150,000 cells/well (for CRD-BP siRNA 
and AON experiments) or 300,000 cells/well (for small molecule experiments), 
depending on the type of experiments. After 24 hours incubation, cells were treated with 
test agents (CRD-BP siRNA, AON or small molecules). 
In CRD-BP siRNA transfection, cells were transfected with CRD-BP siRNA1 (40 
nM), CRD-BP siRNA2 (40 nM) and scramble negative control (SN) (40 nM). SN is a 
double stranded RNA with scramble sequence. For each well in a 6-well plate, 4 μL 
lipofectamine 2000 transfection reagent (Invitrogen, California, USA) was diluted with 
Opti-MEM to make mixture A (total volume 250 μL). To make mixture B (total volume 
of 250 uL), CRD-BP siRNA1, CRD-BP siRNA2 or SN was diluted with Opti-MEM. The 
mixtures were incubated at room temperature for 5 minutes. Then, mixture A and B were 
mixed vigorously, followed by a 20-minute incubation at room temperature. To cells 
which had media renewal (2 mL media/well), 500 μL of the nucleic acid-lipid complexes 
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were added. Cells were transfected again 48 hours after the first transfection using the 
same conditions. Forty-eight hours after the second transfection, cells were harvested as 
described below. 
In AON transfection, cells were transfected with antisense oligonucleotides SM2 
(125 nM), SM6 (125 nM) and SM7 (125 nM). For each well in a 6-well plate, 4 μL 
lipofectamine 2000 transfection reagent (Invitrogen, California, USA) was diluted with 
Opti-MEM to make mixture A (total volume 250 μL).SM2, SM6, or SM7 was diluted 
with Opti-MEM to make mixture B (total volume 250 μL). The following steps were the 
same as described in CRD-BP siRNA transfection above. 
In experiments with small molecules, cells were treated with unbc143 (1 μM, 10 
μM, 20 μM in a final concentration of 2% DMSO), unbc152 (1 μM, 10 μM, 20 μM in a 
final concentration of 2% DMSO) or mock control (2% DMSO). Small molecules were 
first diluted to each concentration with fresh medium. Then, old medium was replaced 
with fresh medium containing small molecules. Forty-eight hours after treatment with the 
small molecules, cells were harvested as described below.  
The reagents for RNA extraction were supplied by the mirVana miRNA isolation kit 
(Invitrogen, California, USA). The protocol used was according to the manufacturer’s 
instructions except for the elution step at the end; cells were rinsed twice with 2 mL PBS 
prior to addition of 200 μL lysis buffer to each well. Lysate was pooled from 2 wells (400 
μL) in a 1.5 mL microcentrifuge tube and was mixed with 40 μL homogenate additive 
followed by incubation on ice bath for 10 minutes. After that, 400 μL of 
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phenol-chloroform were added to lysate, and the mixture was vortexed to mix for 30 
seconds before centrifugation at 10,000 x g for 5 minutes at room temperature. The upper 
phase of the mixture was collected and mixed with 1.25 x 100 % ethanol (room 
temperature). The mixture was mixed well and then loaded into a filter column 
(maximum loading volume 700 μL prior to spinning at 10,000 x g for 15 seconds. The 
flow-through liquid was discarded before 700 μL Wash Solution 1 was added into the 
filter column. Column was washed twice with 500 μL Wash Solution 2/3 by 10,000 x g 
spinning for 15 seconds after flow-through liquid from last wash was disposed. To get rid 
of all the wash solution, column was spun for 1 minute with the same spinning rate before 
elution of RNA. Boiling (95°C) nuclease-free water was used to elute the RNAs from the 
column. The collected RNAs were then quantified using NanoDrop 1000 
spectrophotometer (Thermo Scientific, Illinois, USA).  
3.1.2 cDNA synthesis and Quantitative Real-time Polymerase Chain Reaction 
(qRT-PCR) 
Before cDNA synthesis, I first removed any genomic DNAs from the cell lysate 
using DNase treatment & removal kit (Life Technologies, California, USA). cDNAs were 
then synthesized using iScript cDNA synthesis kit (Bio-Rad Laboratories, California, 
USA) as according to the instructions provided in the kit: 1 μg of total RNA was mixed 
with 1 μL of 10 x DNase I buffer, 1 μL of DNase I and top up to 10 μL with nuclease-free 
water. After 37°C dry bath for 30 minutes, reaction was stopped by adding 2 μL of DNase 
inactivation reagent. Mixture was then incubated at room temperature for 2 minutes and 
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spun at 10,000 x g for 1.5 minutes. Ten μL of the supernatant was collected and mixed it 
with 4 μL of 5 x iScript reaction mix, 1 μL of iScript reverse transcriptase and 5 μL of 
nuclease-free water. Mixture was then placed in the thermocycler and cDNAs were 
synthesized using the following program: 
25 °C 
42°C 
85°C 
4°C 
5 min 
30 min 
5 min 
Indefinite 
    Except for the 1 μL cDNA, the other reaction reagents (Tables 3.3, 3.4 and 3.5) were 
first mixed as a master mix and added after the cDNA was loaded into each well on the 
96-well PCR plate (Axygen, California, USA). Sequences of primers and probes required 
for qRT-PCR are listed in Table 3.2. These primers and probes were purchased from 
Integrated DNA Technologies, Iowa, USA. 
Table 3.2 Sequences of primers and probes 
Primers or probes Sequences References 
CRD-BP forward 
primer 
CRD-BP reverse 
primer 
CRD-BP Taqman 
probe 
5’-AAC CCT GAG AGG  ACC ATC ACT-3’ 
 
5’-AGC TGG GAA AAG ACC TAC AGC-3’ 
 
5’/56-FAM/-TGT TGC AGG GCC GAG CAG 
GA/3BHQ_1/-3’ 
Kato et. al., 
2007 
KRAS forward 
primer 
KRAS reverse 
primer 
KRAS Taqman 
probe 
5’-CGA ATA TGA TCC AAC AAT AGA G-3’ 
 
5’-ATG TAC TGG TCC CTC ATT-3’ 
 
5’/56-FAM/-TAC TCC TCT TGA CCT GCT 
GTG/3BHQ_1/-3’ 
Cogoi et. 
al., 2013 
β-actin forward 
primer 
β-actin reverse 
primer 
5’-TTG CCG ACA GGA TGC AGA AGG A-3 
 
5’-AGG TGG ACA GCG AGG CCA GGA T-3’ 
Mehmood 
et. al., 2016 
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Table 3.3 Reagents for CRD-BP qPCR 
Reaction reagents (for TaqMan assay) Concentration/ volume 
CRD-BP forward primer 400 nM 
CRD-BP reverse primer 400 nM 
CRD-BP probe 200 nM 
IQ SuperMix 12.5 μL 
cDNA 1 μg 
Nuclease-free water Top up to 25 μL 
 
Table 3.4 Reagents for KRAS qPCR  
Reaction reagents (for TaqMan assay) Concentration/ volume 
KRAS forward primer 200 nM 
KRAS reverse primer 200 nM 
KRAS probe 100 nM 
IQ SuperMix 12.5 μL 
cDNA 1 μg 
Nuclease-free water Top up to 25 μL 
 
Table 3.5 Reagents for in β-actin qPCR  
Reaction reagents (for SybrGreen assay) Concentration/ volume 
β-actin forward primer 200 nM 
β-actin reverse primer 200 nM 
IQ SYBRGreen SuperMix 12.5 μL 
cDNA 1 μg 
Nuclease-free water Top up to 25 μL 
Technical triplicates were performed for each reaction. Tubes with no template and 
tubes with no reverse transcriptase were used as controls. After all the reagents were 
added, the 96-well PCR plates were sealed properly, and then ran using their designated 
protocols (see below) in the Multicolor PCR detection system (Bio-Rad, California, USA). 
β-Actin was used as a reference gene. 
qPCR cycle for CRD-BP is: 
95 °C 
95 °C 
53 °C 
2 min 
45 sec 
30 sec  40 X 
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qPCR cycle for KRAS is: 
95 °C 
95 °C 
58 °C 
3 min 
10 sec 
30 sec  
 
qPCR cycle for β-actin is: 
95 °C 
95 °C 
60 °C 
3 min 
10 sec 
30 sec  
Melt curve analysis was performed to assess β-actin qPCR product specificity. 
Temperature increased from 60°C by 0.5°C increments to 95°C; each increment lasted for 
30 seconds. 
The cycle number at which the exponentially accumulated amplified product give a 
detectable fluorescent signal is called threshold cycle (CT). Each cycle would yield 
two-fold increased amplified products. CT of the three replicates are averaged first, and 
the be analyzed using following method: 
First, the CT of the target gene (i.e. KRAS) is normalized to that of the reference 
gene (i.e. β-actin), for both the test sample (i.e. CRD-BP siRNA1 transfected sample) and 
the calibrator sample (i.e. SN transfected sample): 
∆CT (test) = CT (target, test) - CT (reference, test) 
∆CT (calibrator) = CT (target, calibrator) - CT (reference, calibrator) 
Then, the CT of the test sample is normalized to the CT of the calibrator sample: 
∆∆CT = ∆CT (test) - ∆CT(calibrator) 
Finally, the expression ratio is calculated: 
Normalized expression ratio = 2-∆∆CT 
40 X 
40 X 
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3.2 Methodology – Detecting CRD-BP and KRAS protein levels in 
cells 
    According to the results by Mongroo et. al., (2011), CRD-BP knocked down leads to 
down-regulation of KRAS protein expression in SW480 colon cancer cells.  Therefore, 
the first step of my experiment was to confirm their results.  
3.2.1 Cell preparation and protein extraction  
    Please refer to the cell preparation steps described in section 3.1.1.  
When cells were ready for harvesting, they were first washed twice with 2 mL PBS. One 
hundred fifty μL of lysis buffer (see Table 3.6) were then added to each well, and cell 
lysates from two wells were combined into an Eppendorf tube. Three hundred μL of cell 
lysates in each tube were mixed with 1.2 mL of 100% acetone and the mixture were then 
stored in the -20°C fridge overnight.  
Table 3.6 Reagents used for protein lysis buffer 
Protein lysis buffer Volume  
5M NaCl 1.2 mL 
1M Tris-Cl 2 mL 
10% Triton X-100 4 mL 
10% SDS 2 mL 
Water 30.8 mL 
Sterile filtered (0.2 μM) and stored in 4°C  
On the following day, the mixtures were centrifuged at 16,000 x g for 10 minutes in 
the cold room. The acetone was carefully discarded and the precipitate dried in the fume 
hood for 10 minutes. Twenty μL of water was used to resuspend the precipitate in each 
tube. However, the volume of water for dissolving proteins depends on the cell density. If 
cell density was low at the time of harvesting, then the volume of water for pellet 
 51 
 
resuspension will be reduced. Tubes from the same treated sample were combined and 
spun at 10,000 x g for 2 minutes at room temperature. Supernatants were collected, and 1 
μL of supernatant was diluted with 9 μL of water and subjected to protein quantification 
using the Pierce BCA protein assay kit (Thermo Scientific, Illinois, USA).  
3.2.2 Western blot analysis 
Please refer to section 2.1.1 for the description of protein quantification. After 
protein concentration was determined, they were ready for Western blot analysis. 
Western blot analysis consists of three steps: polyacrylamide gel electrophoresis, 
membrane transferring and immunostaining. The reagents used for SDS-PAGE are shown 
in Table 2.2. Twelve μL of protein (15-30 μg) was mixed with 3 μL 5 x SDS buffer (with 
5% β-mercaptoethanol), and then boiled for 10 minutes. Sample proteins and protein 
marker were loaded and the gel was run at 160 voltages for 45 minutes. 
After the gel electrophoresis was done, proteins were transferred from the gel to the 
Amersham Protran Premium 0.45 μm nitrocellulose blotting membrane (GE Healthcare 
Life Sciences, Buckinghamshire, UK). Transferring was performed at 100 voltages for 1 
hour in the cold room. Since proteins would migrate from the negative charge to the 
positive charge, they would attach to the membrane by placing the gel-membrane 
sandwich at a designated electrode direction. The membrane with transferred proteins was 
then blocked with 20 mL of 1x TBST (0.05 M Tris-Cl, 0.03 M NaCl, 0.1% tween 20, pH 
7.4) with 5% skim milk (or 5% BSA, depending on antibody type) on a waver in the cold 
room overnight. Skim milk (or BSA) would attach to the membrane at where no protein 
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binds to, and reduces non-specific binding resulting in reduced background signal in 
immunostaining.  
The next day, membrane was rinsed twice with 1x TBST prior to incubation with 
primary antibodies. Since several target proteins were to be detected, the membrane was 
cut into 2-3 pieces as according to the target protein sizes. Antibodies were first diluted in 
optimized concentrations (see Table 3.7) with 1 x TBST containing 1% skim milk (or 5% 
BSA, depending on antibody type). Then, membranes were incubated with primary 
antibodies on a waver in room temperature for 1 hour (or overnight, depending on 
antibody type) followed by 10-minute washing with 1x TBST for 3 times. After that, 
membranes were incubated with secondary antibodies (see Table 3.7) for 1 hour in room 
temperature on a waver prior to 10-minute washing with 1x TBST 3 times. Reagents from 
the SuperSignal West Pico Chemiluminescent Substrate kit (or SuperSignal West Femto 
Maximum Sensitivity Substrate kit when antibody signal intensity is weak) (Thermo 
Scientific, Illinois, USA) were warmed to room temperature before use. The 3 mL of each 
substrate components from the kit were mixed prior to adding to the membranes. After 5 
minute incubation, membranes were visualized using the FluorChem Q system 
(Proteinsimple, California, USA) and analyzed by AlphaView Q software (ProteinSimple, 
California, USA). β-Actin, GAPDH and thioredoxin were used as reference genes. 
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Table 3.7 Dilutions of primary antibodies and secondary antibodies 
Primary antibody Corresponding Secondary antibody 
IMP-1              
K-Ras              
β-Actin             
GAPDH  
Thioredoxin           
Phospho-MAPK  
Phospho-Akt           
1:1000 
1:500 
1:4000 
1:20000 
1:1000 
1:1000 
1:2000 
Goat anti-mouse IgM-HRP   
Anti-mouse IgG-HRP        
Anti-mouse IgG-HRP        
Anti-mouse IgG-HRP        
Anti-rabbit IgG-HRP  
Anti-rabbit IgG-HRP 
Anti-rabbit IgG-HRP        
1:4000 
1:4000 
1:4000 
1:4000 
1:2000 
1:2000 
1:2000 
IMP1 (D-9; sc-166344), K-Ras (F234; sc-30) and goat anti-mouse IgM-HRP 
(sc-2064) were purchased from Santa Cruz Biotechnology, Texas, USA. Monoclonal 
anti-β-Actin (clone AC-15) and monoclonal anti-GAPDH (clone GAPDH-71.1) were 
purchased from Sigma-Aldrich, Missouri, USA. Anti-thioredoxin/TRX antibody ab26320 
was purchased from Abcam, Cambridge, UK. Phospho-p44/42-MAPK (Erk1/2) 
(Thr202/Tyr204) antibody and phospho-Akt (Ser473) (D9E) XP rabbit mAb were 
purchased from Cell Signaling Technology, Massachusetts, USA. Anti-mouse IgG-HRP 
conjugate and anti-rabbit IgG-HRP conjugate were purchased form Promega, Wisconsin, 
USA. 
To quantify the protein expression, several steps are required:  
The luminescence intensity (I) of the target protein (i.e. KRAS) was first normalized 
to that of the reference protein (i.e. β–actin), for both the test sample (i.e. CRD-BP 
siRNA1 transfected sample) and the calibrator sample (i.e. SN transfected sample). 
Expression (test) = I (target, test) / I (reference, test) 
Expression (calibrator) = I (target, calibrator) /I (reference, calibrator) 
Then, the expression ratio of the target protein is calculated by normalizing the 
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protein expression of the test sample to that of the calibrator sample: 
Expression ratio = Expression (test) / Expression (calibrator) 
Normalized data obtained from qPCR (Section 3.1.2) and Western blot analyses 
were then plotted and statistically analyzed using GraphPad Prism Software. A paired 
T-test with two-tailed distribution was used to analyze the significance of the data. The 
Excel Software was used for the T-test. In the T-test function, the normalized data of all 
the replicates of the test sample (i.e. CRD-BP siRNA treated sample) are entered in 
Array1, and the normalized data of all the replicates of the calibrator sample (i.e. SN 
transfected sample) are entered in Array2. P-value was then be calculated. If P-value ≤ 
0.05, data would be considered as statistically significant. 
3.3 Results and Discussion 
3.3.1 mRNA and protein expression of CRD-BP and KRAS in CRD-BP-knocked 
down colon cancer cells 
    The purpose of this section is to understand the relationship between CRD-BP and 
KRAS at the post-transcriptional and post-translational levels. By comparing their gene 
expressions, we can test the hypothesis on how CRD-BP regulates KRAS and what kind 
of modulation mechanism might exist. As mentioned earlier, I hypothesize that CRD-BP 
might compete with translational repressor(s) in binding to KRAS mRNA. To test this 
hypothesis and to determine whether the relationship between CRD-BP and KRAS 
mRNA exists, I used two specific siRNA against CRD-BP to knockdown CRD-BP 
mRNA levels and measured the expression of KRAS mRNA and protein levels. Both the 
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mRNA and protein levels of CRD-BP and KRAS were assessed in SW480 and CaCO2 
colon cancer cells transfection with the two siRNAs (Table 3.1). If my hypothesis is true, 
knockdown of CRD-BP should repress KRAS translation without affecting KRAS RNA 
level. 
 
Figure 3.1 CRD-BP and KRAS mRNA expression in CRD-BP-knocked down SW480 
cells. SW480 colon cancer cells were transfected with siRNA1, siRNA2, or 
scrambled-negative (SN) as described in section 3.1.1. Results were normalized to mRNA 
level of β–actin and then expressed relative to the SN as shown. Results shown were 
based on four separate biological replicates (n=4). Error bars indicate S.E.M. *P < 0.05, 
**P < 0.01. 
      
Figure 3.2 CRD-BP and KRAS protein expression upon CRD-BP-knocked down in 
SW480 colon cancer cells. (A) SW480 cells were transfected with siRNA1, siRNA2, or 
scrambled-negative (SN) as described in section 3.3.1. Cell lysates collected were 
subjected to Western blot analysis as shown. The result shown is a representative from 
two biological replicates. (B) The levels of CRD-BP and KRAS protein levels in siRNA1- 
and siRNA2-transfected cells were normalized to that of β–actin and then expressed 
relative to the SN as shown. Results shown are the average data from (A) and another 
separate biological replicate (n=2). Error bars indicate S.E.M. 
Mongroo et. al. (2011) showed that upon knockdown of CRD-BP (decreased of 75%) 
B A 
** 
 
 
** 
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in SW480 cells using a specific siRNA against CRD-BP mRNA, there was approximately 
60% decreased in KRAS protein level. However, the authors did not report any changes 
in mRNA levels of CRD-BP and KRAS (Mongroo et. al., 2011). Using two different 
siRNAs against CRD-BP, I found that no significant change in the KRAS mRNA levels 
was observed upon the knockdown of CRD-BP (Figure 3.1). However, knockdown of 
CRD-BP (protein and mRNA levels) led to 50% decreased in KRAS protein levels 
(Figure 3.2), which is in good agreement with the results by Mongroo et. al. (2011). 
These results imply that CRD-BP most likely influences KRAS expression at the level of 
translational control. It agrees with the hypothesize that CRD-BP competes with KRAS 
translation repressor(s) for binding to the KRAS transcript. The CRD-BP commonly 
holds and protects KRAS transcripts and allows them to process to translation. However, 
in cases where there is a reduced level of CRD-BP leading to a reduced amount of 
CRD-BP bound to KRAS transcript (for instance in CRD-BP-knocked down cells), 
translation repressor(s) (such as let-7 microRNA family) would be free to bind to KRAS 
mRNA and suppress its translation leading to less amount of KRAS proteins. The KRAS 
gene is one of the targets of tumor suppressor microRNA let-7. Since both CRD-BP and 
let-7 can target the 3’UTR of KRAS mRNA, CRD-BP might prevent let-7 binding to 
KRAS mRNA and leading to translation repression (Johnson et. al., 2005; Bell et. al., 
2013).  
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Figure 3.3 CRD-BP and KRAS protein expression upon CRD-BP-knocked down in 
CaCO2 cells. (A) CaCO2 colon cancer cells were transfected with siRNA1, siRNA2, or 
scrambled-negative (SN) as described in section 3.3.1. Cell lysates collected were 
subjected to Western blot analysis as shown. The result shown is a representative from 
two biological replicates. (B) The levels of CRD-BP and KRAS protein levels in siRNA1- 
and siRNA2-transfected cells were normalized to that of thioredoxin and then expressed 
relative to the SN as shown. Results shown are the average data from (A) and another 
biological replicate (n=2). Error bars indicate S.E.M. 
To simply assess effect of CRD-BP siRNAs on the KRAS protein levels in the other 
colon cancer cell lines, I conducted the same transfection and Western blot analysis in 
CaCO2 cells. In contrast to SW480 cells, there was no significant decrease in both 
CRD-BP and KRAS protein levels in CaCO2 cells upon treatment with siRNAs against 
CRD-BP (Figure 3.3). According to the report by Mongroo et. al. (2011), CRD-BP 
mRNA levels was around 13-fold higher in CaCO2 cells than SW480 cells. Therefore, it 
is possible that the abundant CRD-BP present in CaCO2 cells could be masking the effect 
of the siRNAs and hence no visible knockdown of CRD-BP was observed in CaCO2 cells. 
Such results showed that CaCO2 cells are less susceptible to siRNAs against CRD-BP. 
3.3.2 Effect of AON on CRD-BP and KRAS gene expression 
After establishing the relationship between CRD-BP and KRAS mRNA in SW480 
cells, the next step was to assess the AON candidate inhibitors on the cells. SM6 and SM7 
B A 
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were shown to block the binding of CRD-BP to KRAS RNA to 50% at 4.72 nM and 1.18 
nM respectively in an EMSA (Sebastian Mackedenski, unpublished data). I first measured 
the mRNA levels of CRD-BP and KRAS in SW480 cells using qRT-PCR. Then, the 
Western blot analysis was performed on both SW480 and CaCO2 colon cancer cell lines 
to assess the protein levels of CRD-BP and KRAS. The AONs were expected to bind to 
KRAS mRNA at the binding site of CRD-BP on KRAS mRNA. Without the binding of 
CRD-BP, a hypothetical translational repressor could bind to KRAS mRNA and block 
translation. If SM6 and SM7 bind to KRAS mRNA in cells, a decline in KRAS protein 
expression is expected.   
 
Figure 3.4 CRD-BP and KRAS mRNA expression in SW480 cells transfected with AONs. 
SW480 colon cancer cells were transfected with SM2, SM6, or SM7 as described in 
section 3.1.1. Results were normalized to mRNA level of β–actin and then expressed 
relative to the SM2 as shown. Results shown were based on four separate biological 
replicates (n=4). Error bars indicate S.E.M. 
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Figure 3.5 CRD-BP and KRAS protein expression in SW480 cells transfected with AONs. 
(A) SW480 colon cancer cells were transfected with SM2, SM6, or SM7 as described in 
section 3.1.1. Cell lysates collected were subjected to Western blot analysis as shown. The 
result shown is a representative of four biological replicates (n=4). (B) The levels of 
CRD-BP and KRAS protein levels in SM6- and SM7-transfected cells were normalized to 
that of β–actin and then expressed relative to the SM2 as shown. Results shown were 
based on (A) and three other biological replicates (n=4). Error bars indicate S.E.M. *P < 
0.05, **P < 0.01. 
    Because DNA sequences are more stable for long-term storage and more economical 
to generate, the antisense oligonucleotides were made as deoxyribonucleotides for in vitro 
EMSA and FP experiments. However, single stranded RNA bases have higher affinity 
than single stranded DNA bases in cells and in vitro. Therefore, we decided to generate 
these antisense oligonucleotides as more stable 2’O-methylated version of RNA bases for 
cell-based experiments. Since the RNase H cleaves only DNA-RNA hybrids and should 
not degrade the AON-KRAS RNA complex, it is expected that KRAS RNA level kept 
stable after cells were transfected with AONs (Figure 3.4). 
As is shown in Figure 3.5, antisense oligonucleotides SM6 and SM7, which were 
designed against KRAS transcript, significantly decreased CRD-BP levels. However, no 
obvious KRAS inhibitory effect was seen with SM6 and SM7. Since the AONs inhibitors 
are likely to interact with KRAS mRNA thereby occluding KRAS mRNA-bound 
CRD-BP leading to the accumulation of CRD-BP, it is possible that AONs inhibitors 
A B 
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might regulate CRD-BP through disrupting the expression of other CRD-BP targeted 
genes. For example, β-catenin can promote CRD-BP transcription through binding to 
CRD-BP promoter (Gu et. al., 2008). Two of the CRD-BP direct targets, βTrCP1 and 
IGF2 mRNA, however, are involved in the modulation of β-catenin, implying the 
feedback regulation of CRD-BP (Noubissi et. al., 2006; Djiogue et. al., 2013). When 
more CRD-BP binds to these mRNAs, up-regulation of βTrCP1 and down-regulation of 
IGF2 inactivate β-catenin, resulting in suppression CRD-BP promoter-driven 
transcription.  
The sequences of SM6 and SM7 cover the two tandem stem-loops of KRAS 
transcript, which is considered as the minimum binding region of CRD-BP. When SM6 
and SM7 hybridize with KRAS mRNA, they might take the place of CRD-BP to compete 
with translation repressor(s) at the same binding region on KRAS mRNA, and therefore 
still inhibit translation repression.  
      
Figure 3.6 CRD-BP and KRAS protein expression in CaCO2 cells transfected with AONs. 
(A) CaCO2 colon cancer cells were transfected with SM2, SM6, or SM7 as described in 
section 3.1.1. Cell lysates collected were subjected to Western blot analysis as shown. The 
result shown is from one biological replicate. (B) The levels of CRD-BP and KRAS 
protein levels in SM6- and SM7-transfected cells quantified from (A) were normalized to 
that of β–actin and then expressed relative to the SM2 as shown. The results shown is one 
biological replicate (n=1). 
A B 
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 To determine whether AONs SM6 and SM7 have similar inhibitory effect on other 
colon cancer cell line, I performed similar experiments on CaCO2 cell line. My 
preliminary results showed that although SW480 and CaCO2 are both colorectal cancer 
cells, no obvious inhibition on CRD-BP expression was observed in CaCO2 (Figure 3.6). 
Both SW480 and CaCO2 are colon cancer cell lines, but their responses to the AON 
inhibitors were different. As shown in Figure 3.3, CaCO2 was insensitive to CRD-BP 
silencing and the similar reasons may account for why CaCO2 cells were irresponsive to 
the AONs.  
3.3.3 Effect of small molecules, unbc143 and unbc152, on CRD-BP and KRAS gene 
expression 
     According to the results from fluorescence polarization experiments (Figure 2.8), 
the small molecule candidates, unbc143 and unbc152, were able to decrease 
CRD-BP-KRAS RNA binding by about 20% and 40% respectively. Therefore, it will be 
interesting to see if both unbc143 and unbc152 have any effect on KRAS expression in 
SW480 colon cancer cells where the relationship between CRD-BP and KRAS mRNA 
exists. RT-qPCR analysis was conducted in SW480 colon cancer cells and Western blot 
analysis was conducted in both SW480 and HT29 colon cancer cells. In contrast to AONs, 
small molecules might act in a different way in blocking the CRD-BP-KRAS mRNA 
interaction. Since proteins are tend to recognize the structure of molecules while RNAs 
are tend to recognize the sequence, I hypothesize that the small molecules displaying 
complex structures are likely to bind CRD-BP protein rather than KRAS mRNA. If this is 
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true, then KRAS mRNA would be bound by translation repressor(s) and translation would 
be blocked.  
Lastly, to investigate whether the unbc152 inhibitory effect on KRAS expression 
would suppress the KRAS downstream signaling pathways, I carried out Western blot 
analysis using cell lysates from SW480 cells treated with the small molecule and examine 
the expression of phospho-Akt and phospho-MAPK, which are phosphorylated and 
activated by KRAS signaling. If KRAS activity was inhibited by the small molecule, then 
both phospho-Akt and phospho-MAPK expression are expected to be suppressed.  
 
Figure 3.7.CRD-BP and KRAS mRNA expression in unbc143-treated SW480 cells. 
SW480 colon cancer cells were treated with three different concentrations (1, 10, 20 µM) 
of unbc143 as described in section 3.1.1. Results were normalized to mRNA level of β–
actin and then expressed relative to DMSO-treated control as shown. Results shown were 
based on four separate biological replicates (n=4). *P < 0.05, **P < 0.01. 
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Figure 3.8 CRD-BP and KRAS protein expression in unbc143-treated SW480 cells. The 
levels of CRD-BP and KRAS in unbc143-treated samples, as quantified using Western 
blot analysis, were normalized to protein level of β–actin. SW480 colon cancer cells were 
treated with three different concentrations (1, 10, 20 µM) of unbc143 as described in 
section 3.1.1. Results were then expressed relative to DMSO-treated control as shown. 
Results shown were based on four separate biological replicates (n=4). Error bars indicate 
S.E.M. 
As is shown in Figure 3.7 and Figure 3.8, both protein and mRNA levels were 
relatively stable when unbc143 was added to SW480 cells, indicating that unbc143 had 
no significant effect on KRAS protein expression in cells. 
 
Figure 3.9 CRD-BP and KRAS mRNA expression in unbc152-treated SW480 cells. 
SW480 colon cancer cells were treated with three different concentrations (1, 10, 20 µM) 
of unbc152 as described in section 3.1.1. Results were normalized to mRNA level of β–
actin and then expressed relative to DMSO-treated control as shown. Results shown were 
based on four separate biological replicates (n=4). Error bars indicate S.E.M.*P < 0.05, 
**P < 0.01. 
* * ** 
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Figure 3.10 CRD-BP and KRAS protein expression in unbc152-treated SW480 cells. (A) 
SW480 colon cancer cells were treated with three different concentrations (1, 10, 20 µM) 
of unbc152 as described in section 3.1.1. Cell lysates collected were subjected to Western 
blot analysis as shown. The result shown is a representative of four biological replicate 
(n=4). (B) The levels of CRD-BP and KRAS protein levels in unbc152-treated cells were 
quantified and normalized to that of GAPDH and then expressed relative to the 
DMSO-treated control as shown. Results shown were based on (A) and three other 
biological replicates (n=4). Error bars indicate S.E.M. *P < 0.05, **P < 0.01. 
    Although changes at the KRAS mRNA levels were not as marked as the KRAS 
protein levels, we could still see the similar decline trend as the concentration of unbc152 
increases. In fact, about 40% inhibition on KRAS mRNA expression was observed at 20 
μM of unbc152 (Figure 3.9). KRAS protein levels were significantly reduced to around 
50% in the presence of 10 μM unbc152 (Figure 3.10). This result is consistent with the 
hypothesis that unbc152 could block the interaction between CRD-BP and KRAS mRNA 
in cells as it did in vitro (Figure 2.8).  
A B 
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Figure 3.11 CRD-BP and KRAS protein expression in unbc152-treated HT29 cells. (A 
and B) HT29 colon cancer cells were treated with three different concentrations (1, 10, 20 
μM) of unbc152 as described in section 3.1.1. Cell lysates collected were subjected to 
Western blot analysis as shown. The result shown is a representative of three biological 
replicates respectively (n=3). (C and D) The levels of CRD-BP and KRAS protein in 
unbc152-treated cells were quantified and normalized to that of β–actin and then 
expressed relative to the DMSO-treated control as shown. Results shown were based on 
four separate biological replicates, respectively (n=3). Error bars indicate S.E.M. *P < 
0.05, **P < 0.01. 
To assess whether the inhibitory effect of unbc152 also exists in other colon cancer 
cell line, I performed similar experiments on HT29 colon cancer cell line. Results showed 
that indeed KRAS protein levels were significantly decreased to around 40% at 10 μM of 
unbc152 (Figure 3.11 B and D). To my surprise, I found that a significant increase in 
CRD-BP protein levels (3-7 fold) in the presence of unbc152 (Figure 3.11 A and C). 
CRD-BP was found to up-regulate several proto-oncogene expressions through shielding 
their transcripts from mRNA degradation (Nielsen et. al., 2004; Noubissi et. al., 2006). 
CRD-BP binds to the 3’UTR and coding region of c-myc and prevents endoribonuclease 
attack on c-myc transcript (Doyle et. al., 1998). KRAS is also one of the targets that 
C 
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interact with CRD-BP physically. Similarly, CRD-BP could also bind to the 3’UTR and 
coding region of KRAS transcript (Mongroo et. al., 2011; Nielsen et. al., 2004; Noubissi 
et. al., 2006). I propose that while unbc152 docks on CRD-BP and disable its binding 
affinity to KRAS mRNA, KRAS mRNA loses the normal shielding protection from 
CRD-BP and therefore subjected to mRNA degradation. With decreased KRAS transcript 
levels, less KRAS proteins are translated.  
In terms of the up-regulated KRAS protein observed by unbc152 in HT29 cell lines 
at 1 μM, I hypothesize that there might be cell stress response happening. Stöhr et. al. 
(2006) found that CRD-BP could stabilize its specific targets (such as c-myc) by forming 
stress granule when cells were treated with arsenate. As an integrated stress response, 
c-myc transcript level in stressed cells was more than 2 folds higher than that of 
non-stressed cells after transcription was blocked for 1 hour. A possible explanation for 
my results is that at low concentration, unbc152 has no effect on most of the 
CRD-BP-KRAS mRNA interaction in cells; rather this dispiro pyrrolizidine molecule 
might induce cellular stress. KRAS mRNA might be stabilized during the cellular stress 
and the transcription of KRAS is up-regulated. After concentration of unbc152 is 
increased, the small molecule inhibitor start to play its specific role in blocking the 
CRD-BP-KRAS mRNA interaction and this effect overwhelmed the one of cellular stress 
response.  
Besides KRAS expression, changes in CRD-BP expression were also observed in 
these experiments. CRD-BP mRNA levels in HT29 is about 19 folds lower than that in 
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SW480 (Mongroo et. al., 2011).The relatively low expression of CRD-BP expression in 
HT29 cells allows changes in CRD-BP expression to be more detectable. Since the 
CRD-BP levels in SW480 treated with unbc152 were not consistent in each biological 
replicate (data not shown), I proposed that CRD-BP regulation in SW480 cells might be 
sensitive to different cell stages. Actually, not only the KRAS mRNA but also the other 
CRD-BP transcript targets could not bind to CRD-BP when CRD-BP is occupied by 
unbc152. The Wnt/β-catenin signaling pathway has been shown to regulate CRD-BP 
expression through CRD-BP promoter binding. Being involved in the Wnt/β-catenin 
pathway, βTrCP1 mRNA is destabilized without CRD-BP binding and inactivate 
β-catenin degradation (Noubissi et. al., 2006). Translation of IGF2 is inhibited when 
CRD-BP is binding to IGF2 leader 3 mRNA. If IGF2 leader 3 mRNA is free from the 
CRD-BP, IGF2 would signal suppress β-catenin inhibitor function and increase β-catenin 
activity (Djiogue et. al., 2013).  
   
Figure 3.12 Phopho-Akt and phospho-MAPK protein expression in unbc152-treated 
SW480 cells. (A) SW480 colon cancer cells were treated with three different 
concentrations (1, 10, 20 μM) of unbc152 as described in section 3.1.1. Cell lysates 
collected were subjected to Western blot analysis as shown. The result shown is from one 
biological replicate. (B) The levels of phospho-Akt and phospho-MAPK protein in (A) 
were quantified and normalized to that of thioredoxin and then expressed relative to the 
DMSO-treated control as shown. The result shown is from one biological replicate (n=1). 
A B 
 68 
 
As is shown in Figure 3.12, protein levels of both phospho-Akt and phospho-MAPK 
showed decreasing trends with the increasing dose of unbc152, and around 50% 
inhibition was observed in both proteins at 20 μM of unbc152.  
Such results show that the suppression on KRAS expression by unbc152 leads to the 
inhibition of downstream KRAS signaling pathway in a KRAS-dependent manner. Since 
both Akt and MAPK are activated by KRAS signaling, the suppression of KRAS levels 
leads to inactivation of Akt and MAPK. In Raf/MEK/ERK signaling pathway, 
GTP-bound KRAS activates Raf protein to phosphorylate MEK (MAPK kinase), which 
would then phosphorylate and activate ERK (MAPK). When KRAS is mutated or 
over-expressed, continuously activated state of GTP-KRAS would amplify the 
Raf/MEK/ERK signaling pathway and disrupt normal cell differentiation and apoptosis 
(Dhillon et. al., 2007). Courtney et. al. (2010) showed that KRAS is able to bind one of 
the PI3K subunits, p110, and activate PI3K signaling. PI3K promotes PIP2 
phosphorylation to PIP3, and then phosphorylate and activate PDK1 and Akt. Activation 
of Akt direct- or indirectly inhibits the expression of several pro-apoptotic genes 
including BAD, BAX, FOXO, TSC2, GSK3 and p53, and leads to increased cell survival.  
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CHAPTER 4 General Discussion 
4.1 Project general overview 
CRD-BP (mouse), also termed IGF2BP1, IMP1 (human) and ZBP-1 (chicken), was 
first discovered for its high affinity for the coding region instability determinant (CRD) of 
c-myc mRNA and postulated to protect c-myc mRNA from endonuclease attack and RNA 
degradation (Bernstein et. al., 1992; Lemm et. al., 2002). CRD-BP is expressed during 
embryonic development and is barely observed after the birth. Studies show that it 
controls the expression of IGF2 in the late development of embryogenesis by targeting 
the IGF2 leader 3 mRNA and suppressing its translation (Nielsen et. al., 1999). In several 
types of cancers including breast, testicular, lung and colorectal cancers (Doyle et. al., 
2000; Kato et. al., 2007; Hammer et. al., 2005; Ioannidis et. al., 2005, Ross et. al., 2001), 
CRD-BP was found to re-express and is involved in the regulation of cancer-related genes 
such as CD44, c-myc , GLI1, KRAS and MDR-1 (Vikesaa et. al., 2006; Lemm et. al., 
2002; Noubissi et. al., 2009; Mongroo et. al., 2011; Mahapatra et al., 2013). Loss of 
CRD-BP was reported to increase cell adhesion, invadopodia formation and cell 
proliferation (Vikesaa et. al., 2006; Ioannidis et. al., 2005); however, increase of tumor 
cell invasion and migration was also observed in human leukemia and breast cancer with 
CRD-BP knockdown, indicating the essential role of CRD-BP in controlling cancer cell 
development (Liao et. al., 2004; Gu et. al., 2009).   
The RAS family encodes a class of membrane-localized small GTPase and functions 
as signaling switch. As the RAS family member, KRAS has the highest mutational rate in 
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all kinds of human carcinomas. Around 30-40% of colorectal cancers harbor KRAS 
mutations and about 97% of KRAS mutations are located in codons 12 and 13. The most 
frequent mutation happens in codon 12 from GGT to GAT, which disrupts the formation 
of GTPase and results in constantly activated state of the GTPase (Arrington et. al., 2012). 
Since mutation of KRAS leads to continuous binding of KRAS-GTP and failure of GTP 
hydrolysis, pathways related to KRAS downstream signaling such as MAPK and PI3K 
pathway would be constantly activated, leading to cellular effects related to oncogenesis 
such as cell proliferation and migration (Zenonos and Kyprianou, 2013; Dhillon et. al. 
2007). Recent study also reported that KRAS-GTP dimers or higher order clusters are 
essential components to activate MAPK pathway. Elevated phosphor-Erk expression was 
observed by inducing artificial KRAS-GTP dimers, and the massive cell death triggered 
by doxycycline and MEK inhibitor could be restored by addition of dimerization of 
artificial KRAS-GTP dimers (Nan et. al., 2015). CRD-BP binds to the coding region and 
3’UTR of KRAS mRNA, and positively regulates KRAS gene expression (Mongroo et. 
al., 2011). The major goal of this research is to identify inhibitors of CRD-BP-KRAS 
mRNA interaction in vitro and then assessing them for their potential ability to suppress 
KRAS expression in tumor cells. 
4.2 Establishing the FP method to study CRD-BP-KRAS RNA 
interaction 
CRD-BP consists of four hnRNP K-homology (KH) domains and two RNA 
recognition motifs (RRM) (Doyle et. al., 1998). The KH domain is a nucleic acid 
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recognition and binding motif. Each KH domain harbors a highly conserved GXXG loop 
(Valverde et. al., 2008). To investigate the functions of each KH domain in CRD-BP, 
Barnes et. al. (2015) introduced site-directed point mutation at the first glycine of the 
GXXG loop in each of the KH domain. According to the reported EMSA study, CRD-BP 
variants harboring single-point mutation retained their binding ability to c-myc and CD44 
mRNA; however, double-point mutated variants with the exception of KH3-4 di-domain 
significantly reduced the binding or completely abrogated RNA binding. It was therefore 
hypothesized that at least two tandem KH domains are required for CRD-BP to efficiently 
bind to its target transcripts (Barnes et. al., 2015).  
To determine whether the FP method can be used to confirm the EMSA results and 
therefore a valid method to further study the CRD-BP-KRAS mRNA interaction, I 
assessed three KH variants of CRD-BP for binding to fluorescently-labeled CD44 and 
KRAS RNA. As shown in Figure 2.3 (D, E, and F), the previously reported binding 
patterns of CRD-BP to CD44 RNA using EMSA (Barnes et. al., 2015) were also observed 
in the FP assay. For instance, using both EMSA (Barnes et. al., 2015) and FP (Figure 
2.3D), the KH1-2 variant exhibited no binding to CD44 RNA. Similarly, using both 
methods the KH3 variant (Barnes et. al., 2015; Figure 2.3E) showed significantly reduced 
ability to bind to CD44 RNA as compared to the WT CRD-BP. Using the EMSA, the 
KH3-4 variant was found to have binding affinity for CD44 RNA which is comparable to 
the WT CRD-BP (Barnes et. al., 2015); however, using the FP method the KH3-4 variant 
was found to have slightly reduced affinity for CD44 RNA (Figure 2.3F). Such small 
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discrepancy could be attributed to the fact that smaller CD44 RNA (39 nt) was used in the 
FP method as opposed to the 194 nt CD44 RNA used in the EMSA (Barnes et. al., 2015). 
 To gain further confidence, I also used the FP method to study CRD-BP-KRAS 
RNA interaction. Again, the binding patterns observed using the FP method recapitulated 
what were previously reported using the EMSA (Mackedenski and Lee, 2015). Using 
EMSA, the KH1-2 variant had no binding affinity while the KH3 variant showed 
significantly reduced affinity for the KRAS RNA (Mackedenski and Lee, 2015). These 
were also observed using the FP method (Figure 2.3A and B). Interestingly, while the 
KH3-4 variant showed no sign of binding affinity for the KRAS RNA (Mackedenski and 
Lee, 2015) using EMSA, modest binding by this variant was observed using FP (Figure 
2.3C). Again, this could be due to the different sized KRAS RNAs (185 nts for EMSA 
and 44 nts for FP) used in the two different methods. Alternatively, the results may just 
reflect the differences between the two methods used in measuring molecular interactions. 
In EMSA, a snap-shot of molecular interaction is only observed and one does not see a 
dynamic molecular interaction, and any rapid dissociation would lead to an 
under-estimation of the binding affinity (Hellman and Fried, 2007). On the other hand, FP 
measurements are done in real-time and hence it can capture the dynamic molecular 
interaction. 
In summary, I have shown that the developed FP method to study CRD-BP-RNA 
interaction can faithfully reproduce the EMSA results, and hence confirmed the validity 
in using the FP method to conveniently study CRD-BP-RNA interaction. 
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4.3 Identifying small molecule inhibitors for CRD-BP-KRAS RNA 
interaction in vitro 
To identify small molecule inhibitors of CRD-BP-KRAS RNA interaction, I 
screened a small molecule library containing 217 dispiro pyrrolizidine/indanone 
derivatives that were provided by our collaborator at the University Sains Malaysia. 
These small molecules could be classified roughly into 7 main structures with different 
substituents on each structure class. However, some of the small molecules are 
autofluorescent and known to interfere with FP measurements (Lea and Simeonov, 2011). 
In my study, the autofluorescent molecules appeared to show false positive in the FP 
assay (Figure 2.5). The autofluorescent molecules might interrupt with the reporter 
fluorophore in FP assay if their excitation light and emission light spectrum regions are 
overlapped (Simeonov et. al., 2008). Except for the autofluorescent molecules, I found 
that insoluble small molecule compounds could also result in false positive signal during 
the FP assay (data not shown). Large particles such as insoluble compounds could result 
to turbidity in reaction environment and change the normal optical path of the excitation 
and emission light (Owicki, 2000). The insoluble compounds might also disrupt physical 
association between CRD-BP and KRAS mRNA in reaction resulting in false inhibitory 
effect in the FP assay. 
SM7 displayed effective inhibitory effect with an IC50 of 1.18 nM in the EMSA 
analysis where 118 pM of KRAS and 217 nM of CRD-BP were used (Sebastian 
Mackedenski, unpublished data). In the FP assay at 500 nM, SM7 did not show potent 
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inhibitory effect (only around 30% decrease) where 10 nM of KRAS and 500 nM of 
CRD-BP were used. Such differences could be attributed to the differences in the 
properties of the two analytical methods as described in Section 4.2. Also, the sequence of 
SM7 is complementary to the fluorescent-labeled KRAS mRNA and therefore they might 
form a AON-RNA duplex in the FP assay. Although the size of AON is very small (23 
nts), their binding might increase slightly the FA value, leads to less “inhibition”.  
4.4 Assessing inhibitory effect of AONs on CRD-BP and KRAS 
RNA expression in colon cancer cells 
     The AON SM6 and SM7 which are complementary to KRAS mRNA were 
designed to block CRD-BP-KRAS mRNA interaction by targeting KRAS mRNA and 
preventing CRD-BP association with KRAS mRNA. They have been proven to be 
effective in inhibiting CRD-BP-KRAS mRNA interaction in vitro (Sebastian unpublished 
data) and are expected to knockdown KRAS expression if they truly function to disrupt 
CRD-BP-KRAS mRNA in cells. However, these AONs were found to decrease CRD-BP 
protein expression largely without disrupting mRNA levels of CRD-BP and KRAS 
(Figure 3.4 and Figure 3.5). These results suggest that the interaction between the AONs 
and KRAS transcripts did not affect the stability of KRAS mRNA and protein.   
King et. al. (2014)  reported three AONs against CD44 RNA that could interrupt 
CRD-BP-CD44 mRNA interaction. These AONs were able to inhibit the binding of 
[32P]-labeled CD44 RNA fragment to CRD-BP in EMSA and they were also inhibitory on 
CD44 mRNA expression in cells. CD44 mRNA is protected from decay upon binding of 
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CRD-BP (Vikesaa et. al., 2006), and the AONs against CD44 RNA are expected to bind 
to CD44 transcripts and therefore disabled CRD-BP association with CD44 mRNA. In 
my hypothesis, CRD-BP and KRAS translation repressor(s) are competiting for binding 
to KRAS mRNA. If KRAS-specific AONs bind to KRAS transcripts, they might also 
compete with KRAS translation repressor(s). Only when the AONs could block 
CRD-BP-KRAS mRNA association without disrupting translation repressor(s) binding to 
KRAS mRNA, suppression of KRAS protein translation could happen. SM6 and SM7 
might physically interact with KRAS transcripts at the same site which is targeted by the 
translation repressor(s). In this case, even if the CRD-BP dissociate from KRAS 
transcripts, translation repressor(s) are still unable to bind KRAS transcripts because the 
SM6 and SM7 may remain hybridized to KRAS mRNA.  
 
Figure 4.1 A possible feedback regulation of CRD-BP with its targets 
The interaction between these AONs and KRAS mRNA might disrupt certain 
pathways related to the CRD-BP expression. Given that CRD-BP was knocked down to 
about 40% as shown in Figure 3.5. I propose the following model to explain my 
observations. Upon disruption of CRD-BP-KRAS mRNA interaction by the AONs, more 
CRD-BP is available to interact with its other targeted transcripts, and through such 
interaction in which CRD-BP might be feedback regulated (Figure 4.1). CRD-BP 
promoter is a direct target of β-catenin/TCF complex, and Wnt/β-catenin signaling could 
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up-regulate CRD-BP expression via CRD-BP promoter-driven transcription. With RNA 
silencing knockdown of β-catenin and TCF4, both CRD-BP mRNA and protein levels 
were decreased to around 50%, implying that both β-catenin and TCF are essential for 
CRD-BP expression (Noubissi et. al., 2006; Gu et. al., 2008). The F-box protein βTrCP1 
mRNA, which is one of the four subunits of the SCF E3 ubiquitin ligase complex, is 
bound by CRD-BP at its 5’UTR. Binding of CRD-BP to βTrCP1 mRNA leads to 
accumulation of both βTrCP1 transcript and protein, promoting activation of SCF E3 
ubiquitin ligase and β-catenin proteolysis (Noubissi et. al., 2006). Another example is 
IGF2, whose translation is inactivated by CRD-BP (Djiogue et. al., 2013). IGF2 interacts 
with insulin-like growth factor 1 receptor or insulin receptors to activate the PI3K/Akt 
signaling pathway. This pathway would inactivate GSK3β, which is the β-catenin 
inhibitor, and promote β-catenin expression. Binding of CRD-BP to IGF2 mRNA 
suppresses IGF2 expression, and therefore triggers GSK3β function to inhibit β-catenin. 
Therefore, it is possible that when more CRD-BP is available to bind βTrCP1 and IGF2 
mRNAs, β-catenin would be down-regulated through the above signaling pathways 
resulting in the suppression of CRD-BP promoter-driven transcription.  
4.5 Assessing the inhibitory effect of unbc152 on CRD-BP and 
KRAS expression in colon cancer cells  
    CRD-BP has been shown to stabilize its targeted transcripts (Vikesaa et. al., 2006; 
Noubissi et. al., 2009) or interfere with the translation of transcripts (Nielsen et. al., 1999; 
Stöhr et. al., 2012). In the CRD-BP RNA silencing experiments, KRAS mRNA levels 
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were found to be unaffected although CRD-BP expression was down-regulated (Figure 
3.1). If KRAS mRNA is also shielded by CRD-BP, the knockdown of CRD-BP should 
disrupt the protection on KRAS transcripts leading to its degradation. Since CRD-BP is 
regulating KRAS without affecting KRAS mRNA levels, I hypothesize that CRD-BP 
might compete with KRAS translation suppressors in binding to KRAS transcript 
resulting in the up-regulation of KRAS translation. Figure 3.2 shows that loss of CRD-BP 
leads to the down-regulation of KRAS expression in cells, which is consistent with an 
earlier study by Mongroo et. al. (2011). The authors discovered that the p53-inducible 
gene CYFIP2 is negatively regulated by CRD-BP and the increased mRNA levels of 
CYFIP2 was observed after suppressing CRD-BP expression. KRAS inhibition induced 
by CRD-BP loss could be restored by knocking down CYFIP2, implying a new 
mechanism of KRAS regulation by CRD-BP via CYFIP2 (Mongroo et. al., 2011). 
Besides, let-7 microRNA family targets the 3’UTR of KRAS mRNA and represses KRAS 
translation. Johnson et. al. (2005) observed that loss of let-7 microRNA results in 70% 
increase of RAS (N-, H- and KRAS) expression in HeLa cells. CRD-BP binds to KRAS 
transcript at the 3’UTR might competitively allow the translational process leading to 
increased KRAS expression (Johnson et. al., 2005; Bell et. al., 2013). 
 However, I was surprised to see significant down-regulation of not only the KRAS 
protein expression but also the KRAS mRNA levels upon treatment with unbc152. This 
result suggests another possible regulatory pattern in that CRD-BP could also shield 
KRAS transcript from RNA decay in certain circumstances. CRD-BP knockdown by 
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siRNA happens at the post-transcriptional level, while unbc152 functions at the 
post-translational level. I propose that unbc152 blocked CRD-BP-KRAS mRNA 
interaction by binding to CRD-BP and thereby freeing the KRAS mRNA for nucleolytic 
attack. The RNA silencing using siRNA might turn on or off some signaling pathways 
associated with CRD-BP, while these pathways might not be affected by the action of 
unbc152 on CRD-BP. Besides, the study by Mongroo et. al. (2011) had shown that 
CRD-BP RNA silencing leads to suppression of CRD-BP protein expression with stable 
pre- and mature let-7 miRNA levels. Such results, in combination with my results shown 
in Figure 3.1 that the suppressive effect of CRD-BP siRNA results in CRD-BP transcript 
degradation, suggest that there may be less amount of CRD-BP mRNA-bound let-7 
miRNA. Under these circumstances, it is possible that more let-7 miRNA are free to bind 
to other let-7 targets such as KRAS, resulting in KRAS translation repression. In the 
situation where CRD-BP gene transcription is normal and CRD-BP mRNA still requires 
bound let-7 miRNA, and CRD-BP protein activity/function is blocked by bound unbc152, 
neither CRD-BP protein nor let-7 miRNA binds to KRAS transcripts. Under such 
circumstance, the KRAS transcripts could be exposed to nucleolytic attack resulting in 
decreased KRAS mRNAs and the concomitant decreased in KRAS protein expression. 
 
Figure 4.2 A possible mechanism for up-regulation of CRD-BP  
     Referring to CRD-BP silencing experiments, CRD-BP positively regulate KRAS 
 79 
 
expression through competition with translation repressor(s). However, the KRAS 
expression was decreased despite an increase level of CRD-BP in the unbc152-treated 
experiments in HT29 colon cancer cells (Figure 3.11). For these observations, my 
explanation is when CRD-BP is occupied by unbc152, it might induce certain specific 
selectivity of CRD-BP binding, which will not happen in CRD-BP silencing. Some of the 
CRD-BP targets may or may not bind to CRD-BP depending on whether their binding 
sites on CRD-BP are still exposed (Figure 4.2). For instance, if CRD-BP is still available 
for c-myc mRNA binding, then c-myc expression would be elevated. Noubissi et. al. 
(2010) reported that c-myc protein is able to recognize and interact with a specific DNA 
sequence localized in CRD-BP promoter and promote CRD-BP transcription. In addition, 
c-myc is proved to negatively control mature let-7 microRNA levels, and through which 
targets of let-7 microRNA are up-regulated, including CRD-BP (Mongroo et. al., 2011). 
As mention in Section 4.4, CRD-BP is also regulated by Wnt/β-catenin signaling pathway. 
β-catenin has shown to be a necessary component in triggering CRD-BP transcription 
through interacting physically with the proximal CTTTG-TC element of CRD-BP 
promoter (Gu et. al., 2008). When CRD-BP is bound by unbc152 and to some degree 
could not bind to its targeted mRNAs, as according to Noubissi et. al. (2006) and Djiogue 
et. al. (2013), βTrCP1 mRNA would be down-regulated due to the lack of protection by 
CRD-BP. At the same time, IGF2 expression would be increased because translation 
suppression trigger by CRD-BP would have disappeared. Both mechanisms will result in 
an elevated level of β-catenin, and therefore promote CRD-BP expression.  
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4.6 Unbc152, a small molecule inhibitor of CRD-BP-KRAS RNA 
interaction: implications for future experiments 
Frequent mutation of KRAS happens in several human carcinomas, especially the 
colorectal cancer. Failure of normal KRAS expression disables KRAS GTPase function, 
and leads to the disorder of cell growth (Arrington et. al., 2012; Zenonos and Kyprianou, 
2013; Dhillon et. al. 2007). In this study, I have shown that the small molecule unbc152 is 
a inhibitor of CRD-BP-KRAS RNA interaction and it successfully inhibited KRAS 
expression in two colon cancer cell lines. To our knowledge, this is the first demonstrated 
small molecule capable of disrupting CRD-BP-KRAS RNA interaction in vitro as well as 
specifically suppressing KRAS expression in cancer cells.  This finding is important 
from several perspectives. Firstly, it demonstrates the proof-of-principle that inhibiting 
the function of CRD-BP through disrupting its interaction with KRAS RNA can lead to 
decreased expression of CRD-BP-targeted gene. Secondly, unbc152 potentially represents 
a new class of anti-cancer drugs which act by inhibiting a new molecular pathway, a 
specific protein-RNA interaction.   
 The following are some recommended experiments using unbc152 that could be done 
to further understand the basic mechanism of action of unbc152 and the role of CRD-BP 
and KRAS in cancer biology. (1) To determine whether unbc152 can inhibit KRAS 
expression in different types of cancer cells. (2) To determine what other proteins (e.g. 
c-myc) whose expression may also be suppressed by unbc152. (3) To determine the 
crystal structure of unbc152 in complex with KH34 di-domain of CRD-BP. 
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It is important to determine whether the inhibitory effect of unbc152 on KRAS 
expression is truly unique to colon cancer cells. To address this, one could examine the 
effect of unbc152 on CRD-BP and KRAS gene expressions in a larger panel of colon 
cancer cell lines as well as other cancer cell lines where the protein levels of CRD-BP and 
KRAS are detectable. These would include pancreatic, lung and breast cancer cell lines. If 
the effect of unbc152 differs amongst these cell lines, then one could examine more 
closely the reasons behind such differences. Using unbc152 as a tool to understand such 
differences is important. This is because we will have a better understanding of the 
significance of CRD-BP-RNA interaction in the tumor development as well as whether 
the unbc152-type drug will be effective against the tumor in questions 
As mentioned earlier, I hypothesize that in addition to KRAS mRNA the interaction 
between unbc152 and CRD-BP may shield some the binding sites of other CRD-BP 
targeted transcripts. Like KRAS, this could lead to suppressed protein expression of these 
targeted genes and suppressed phenotype. To address this, a global scale protein 
expression using proteomics could be done upon treatment of cells with unbc152. Base on 
the proteomics results, one could then design phenotype assays to examine the effect of 
unbc152 on cancer cell phenotype. 
The on-going research in Dr. Lee’s lab suggests that unbc152 is indeed targeting 
CRD-BP at the KH34 di-domain (Victor Liu, unpublished data). To confirm this, it is 
important to determine the crystal structure of unbc152 in complex with the KH34 
di-domain. This experiment should be doable given that the KH34 di-domain of CRD-BP 
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in complex with β-actin RNA has been successful (Chao et. al., 2010). With the crystal 
structure of unbc152-KH34 domain complex, one could then use the information to 
logically design inhibitors which can potentially be more potent than unbc152. 
In addition to the above proposed experiments, animal model studies are required in 
the process of developing unbc152 as a potential new anti-cancer drug. 
4.7 Summary  
The observation that KRAS protein is suppressed by CRD-BP silencing in the 
absence of decreased KRAS mRNA, suggests that the regulation of CRD-BP on KRAS is 
at the level of post-transcription. Since CRD-BP has been shown to physically interact 
with KRAS RNA (Mongroo et. al., 2011), there might be certain translational repressor(s) 
that could block KRAS translational process by competing with CRD-BP in binding to 
KRAS mRNA. Loss of CRD-BP allows the translational repressor(s) to interact with 
KRAS mRNA leading to KRAS protein repression.  
In the AON transfection experiments, both SM7 and SM6 had no effect on the 
KRAS protein expression. Such results also support the notion that translational 
repressor(s) might compete with CRD-BP at the same binding sites on KRAS transcripts. 
Depending on whether the AONs bind to KRAS mRNAs at the translational repressor 
binding sites, this might lead to differential effect on the KRAS gene expression. The 
sequences of SM6 and SM7 complementary to KRAS mRNA might overlap with that of 
translation repressor(s) and inactivated the translational suppression. Surprisingly, both 
SM6 and SM7 knocked down CRD-BP levels dramatically to less than 50%, which 
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suggests the feedback regulation of CRD-BP. Accumulated CRD-BP that are free from 
KRAS transcripts might promote interactions with other CRD-BP binding targets, such as 
IGF2 and βTrCP1 mRNAs, and lead to negative regulation of CRD-BP (Noubissi et. al., 
2006; Djiogue et. al., 2013). 
The only small molecule inhibitor which was effective in cells is unbc152.  
Unbc152 decreases both KRAS mRNA (decreased to 60% at 20 µM) and protein levels 
(decreased to 40-60% at 10 µM) in colon cancer cells. This suggests that KRAS 
expression is regulated at the transcriptional and post-transcriptional levels. Although I 
earlier hypothesized that the regulation of KRAS is likely at the translational level as seen 
with the CRD-BP silencing experiments, it is not surprising to see that KRAS expression 
can also be regulated by multiple pathways under different circumstances. This is 
especially true where the mechanisms of actions of CRD-BP siRNAs and unbc152 are 
totally different. Noticeable increases of CRD-BP protein expression (3 to 7-fold increase) 
were observed in HT29 colon cancer cells after unbc152 treatment. Unbc152 is expected 
to block CRD-BP-KRAS mRNA interaction by associating with CRD-BP, which 
probably changes the exposed binding sites or even the tertiary structure of CRD-BP, 
thereby limiting CRD-BP binding ability to other targeting transcripts. In this case, not 
only KRAS but also other CRD-BP targeting genes might be regulated by unbc152. After 
associating with unbc152, some of the binding sites on CRD-BP might be shielded from 
certain RNAs and some might still be exposed, which might results in binding selectivity 
of CRD-BP. It is possible that CRD-BP binds to RNAs such as c-myc and β-catenin that 
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could positively feedback regulate itself, (Noubissi et. al., 2010; Gu et. al., 2008), or 
disable binding of RNAs such as IGF2 and βTrCP1 that negatively feedback regulate 
CRD-BP (Noubissi et. al., 2006; Djiogue et. al., 2013). In the preliminary Western blot 
assay of phospho-Akt and phospho-MAPK, knockdown of both proteins after unbc152 
treatment indicates that unbc152 inhibitory effect on KRAS expression also 
down-regulates the downstream KRAS signaling pathways. Such results confirm that 
unbc152 can inhibit KRAS-mediated downstream signaling pathway and suggest that it 
could inhibit KRAS-mediated cancer cell phenotype such as cell growth.   
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